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Malignant lymphomas can involve the skin either primarily or secondarily. The term 
“primary cutaneous lymphoma” refers to various T-cell and B-cell malignancies that 
present in the skin without evidence of extracutaneous disease at the time of diagnosis. It is 
important to differentiate these primary cutaneous T-cell lymphomas (CTCL) and primary 
cutaneous B-cell lymphomas (CBCL) from their nodal counterparts, that can involve the 
skin secondarily, since they have a completely different clinical behaviour and prognosis 
and most often require different therapeutic approaches. Primary cutaneous lymphomas are 
the second most common group of extranodal lymphomas after the lymphomas of the 
gastrointestinal tract, with an estimated annual incidence of 1:100.000. While in systemic 
non-Hodgkin lymphomas the large majority is derived from a population of atypical B-
cells, in the skin only 20-25% are CBCL; the remainder mainly consist of CTCL.1 In the 
United States the reported incidence of CBCL is even lower, being approximately 4.5%.2
Until recently, there has been much controversy regarding the terminology and 
classification of CBCL, which may have come to an end with the publication of the WHO-
EORTC consensus classification for cutaneous lymphomas.3 In this classification three 
main types of CBCL are described: primary cutaneous marginal zone B-cell lymphoma 
(PCMZL), primary cutaneous follicle centre lymphoma (PCFCL) and primary cutaneous 
diffuse large B-cell lymphoma, leg type (PCLBCL, LT). In addition, a category of primary 
cutaneous diffuse large B-cell lymphoma, other (PCLBCL, other) was included.
This thesis includes a number of clinical, clinicopathologic and molecular studies 
in different groups of CBCL. The aims of these studies were (1) to validate the clinical and 
prognostic significance of the WHO-EORTC classification, (2) to identify and validate 
(new) diagnostic and prognostic markers, (3) to evaluate the clinical significance of current 
staging procedures and of a new clinical staging system in CBCL, (4) to evaluate the 
efficacy of radiotherapy in the treatment of different types of CBCL, and (5) to formulate 
consensus recommendations for the management of these diseases.
In this introductory chapter a brief historical overview of the classification of 
CBCL and a short description of the different types of CBCL as currently recognized in the 
WHO-EORTC classification, will be presented first. In addition, the background of the 
issues investigated in this thesis will be discussed. 
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Historical overview of the classification of CBCL 
Until the early 1980’s CBCL were not recognized as distinct disease entities. Malignant B-
cell proliferations in the skin were considered invariably as manifestations of systemic 
disease and classified by systems used by hematopathologists for systemic lymphomas. 
Patients with a B-cell proliferation in the skin who showed a good clinical response to local 
treatment and had a favourable prognosis, were regarded as having a benign condition (so 
called pseudolymphoma).4-7
In the late seventies, the introduction  of immunohistochemistry had a major 
impact on the diagnosis and classification of B-cell proliferations in the skin. By accepting 
monotypic immunoglobulin light chain expression on tissue sections of skin biopsies as 
golden standard for the diagnosis of malignant B-cell lymphoma, it became possible to 
distinguish between malignant B-cell lymphomas and reactive B-cell proliferations. 
Moreover, it became clear that B-cell lymphomas can be confined to the skin without any 
systemic disease being present. This simple distinction between primary and secondary 
cutaneous B-cell lymphomas proved extremely important. According to the criteria of the 
Kiel classification, that was in use in these days, most CBCL were classified as 
immunocytoma, centroblastic/centrocytic lymphoma, centroblastic lymphoma or 
immunoblastic lymphoma. Studies on well-defined groups of patients showed that these 
different types of CBCL had a highly distinctive clinical presentation and often another 
clinical behaviour and prognosis as compared to their systemic counterparts. These studies 
led to the delineation of distinct types of CBCL, which were however not recognized 
separately in the existing classification schemes used for nodal lymphomas, and were 
therefore often treated inappropriately. In 1994, Willemze and co-workers proposed a 
separate classification scheme for primary cutaneous lymphomas, thereby using the 
terminology of the updated Kiel classification to define distinct disease entities (see Table 
1).8 This proposal was extensively discussed within the EORTC Cutaneous Lymphoma 
Group (EORTC-CLG) and was formalised in 1997 with the publication of the EORTC 
classification for primary cutaneous lymphomas.1 In this classification three main types 
of CBCL were distinguished: primary cutaneous immunocytoma, later called primary 
cutaneous marginal zone B-cell lymphoma (PCMZL), primary cutaneous follicle centre cell 
lymphoma (PCFCCL) and primary cutaneous large B-cell lymphoma of the leg (PCLBCL-
leg). The distinction between the latter two groups was based on the observation that 
patients with tumours on the leg(s) had a much more aggressive clinical behaviour as 
compared to patients presenting with tumours on the head or trunk.9
In 2001 the WHO classification for tumours of hematopoietic and lymphoid 
tissues was published as a successor of the REAL classification.10;11 This classification did 
not recognize CBCL as distinct disease entities.  PCMZL was included in the broad 
category of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid 
tissue. PCFCCL with a (partially) follicular growth pattern, were classified as cutaneous 
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follicle centre lymphoma, which was considered as a variant of follicular lymphoma (FL), 
while PCFCCL with a diffuse growth pattern were classified as diffuse large B-cell 
lymphoma (DLBCL). The group of PCLBCL-leg was neither acknowledged as a distinct 
disease entity and was also classified as DLBCL. The classification of CBCL according to 
the different classification schemes is presented in Table 1. 
The differences in terminology and definition of the three main types of CBCL 
between the EORTC and WHO classifications resulted in much debate and confusion.12-15
The main point of discussion was formed by the group of  PCFCCL. While this term 
resembles that of FL in the WHO classification, it is defined in a different way. FL denotes 
a neoplasm of follicle centre B-cells (a mixture of centrocytes and centroblasts), which has 
at least a partially follicular growth pattern.11 FL is graded by the proportion of 
centroblasts, using a 3-grade system. The histological grade correlates with prognosis, with 
grades 1 and 2 showing an indolent clinical course, and grade 3 being more aggressive. The 
majority of FL is characterized by the presence of the characteristic chromosomal 
translocation t(14;18), resulting in overexpression of the anti-apoptotic protein Bcl-2.16-19 In 
contrast, the term PCFCCL was introduced as an encompassing term for cutaneous 
lymphomas composed of cells with the morphology of follicle centre B-cells (centrocytes 
and centroblasts), regardless of their growth pattern.20-23 Moreover, PCFCCL had an 
indolent clinical behaviour, irrespective of the proportion of centroblasts and thus, 
histological grading had no prognostic significance. In addition, PCFCCL generally showed 
no expression of Bcl-2 and the t(14;18) could only be identified in a small minority of 
cases.24-26 However, because of the rarity of the disease, (hemato)pathologists were 
generally not familiar with this entity, and  PCFCCL with a diffuse growth pattern were 
generally classified as DLBCL, leading to unnecessary aggressive treatment with 
multiagent chemotherapy.
To put an end to this ongoing controversy, in 2003 and 2004 consensus meetings 
were organized, in which representatives of the EORTC and the WHO systems succeeded 
to combine the best of the two systems and to reach agreement on a consensus 
classification, which was termed the WHO-EORTC classification for cutaneous 
lymphomas. In this classification four categories of CBCL were recognized, which will be 
discussed below and are summarized in Table 2. 
CBCL in the WHO-EORTC classification for cutaneous lymphomas
Primary Cutaneous Marginal Zone B-cell Lymphoma (PCMZL), is an indolent lymphoma 
composed of small B cells including marginal zone (centrocyte-like) cells, 
lymphoplasmacytoid cells and plasma cells. The marginal zone cells express CD20, CD79a 
and Bcl-2, but are negative for CD5, CD10 and Bcl-6.27;28 The plasma cells show 
monotypic cytoplasmic immunoglobulin light chain expression (kappa or lambda) on 
paraffin sections. This category includes cases previously classified as primary cutaneous 
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immunocytoma29, cases of cutaneous follicular lymphoid hyperplasia with monotypic 
plasma cells29;30 and rare cases of primary cutaneous plasmacytoma.31 Clinically, PCMZL 
are characterized by red to violaceous papules, plaques or nodules preferentially localized 
on the trunk or extremities. They have a tendency to recur in the skin, but extracutaneous 
dissemination is exceedingly rare, which is reflected in the excellent 5-year survival rate of 
close to 100%.29;32-35
Primary Cutaneous Follicle Centre Lymphoma (PCFCL) is defined as a tumour of 
neoplastic follicle centre cells, usually a mixture of centrocytes (small and large cleaved 
follicle centre cells) and variable numbers of centroblasts (large noncleaved follicle centre 
cells with prominent nucleoli). It includes cases with a follicular, a follicular and diffuse 
and a diffuse growth pattern. The neoplastic follicle centre cells express CD20, CD79a and 
Bcl-6. CD10 is particularly observed in cases with a (partly) follicular growth pattern. 
Recent gene expression studies revealed that these PCFCL have the gene expression profile 
of germinal center B-cell (GCB)- like DLBCL.36 Consistently, the neoplastic B-cells 
generally do not express Bcl-2, MUM-1 and FOXP1.24;27;28;36-40 Clinically, PCFCL 
generally present with solitary or grouped plaques and tumours, preferentially located on 
the head or trunk.20;22;23;41 Extracutaneous dissemination is uncommon and their prognosis 
is excellent, irrespective of the growth pattern or the number of blast cells (5-year survival 
of more than 95%).20;22;23;38;40-42   
Primary Cutaneous diffuse Large B-cell Lymphoma, Leg Type (PCLBCL, LT) are diffuse 
large B-cell lymphomas with a predominance or confluent sheets of centroblasts and 
immunoblasts. These neoplastic cells express CD20, CD79a and, since PCLBCL, LT have 
the gene expression profile of activated B-cell (ABC)-like DLBCL, the great majority of 
cases strongly express Bcl-2, MUM-1 and FOXP1.36 Bcl-6 is expressed in most cases, 
while CD10 is generally absent.28;36;39;43-45 Characteristically, they present with tumorous 
skin lesions on the (lower) leg(s), but uncommonly can arise at other sites as well. The 
disease affects predominantly elderly patients, and females are more affected than males. 
These lymphomas often disseminate to extracutaneous sites and have an intermediate 
prognosis with a 5-year survival of approximately 50%.9;43;46;47  
Primary Cutaneous diffuse Large B-cell Lymphoma, other (PCLBCL, other) is used for rare 
cases of primary cutaneous diffuse large B-cell lymphomas that do not belong to the group 
of PCFCL or PCLBCL, LT. These include morphologic variants, such as rare cases of 
anaplastic or plasmablastic lymphoma and intravascular large B-cell lymphomas presenting 
primarily in the skin. These latter entities are exceedingly rare and will not further be 
discussed in this thesis.
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Table 1. 
Classification of primary cutaneous B-cell lymphomas according to the Kiel classification, the EORTC classification, the WHO 
classification and the WHO-EORTC classification
Kiel classification EORTC classification WHO classification WHO-EORTC classification
Immunocytoma Primary cutaneous 
immunocytoma/ marginal 
zone B-cell lymphoma
Extranodal marginal zone B-cell 
lymphoma of mucosa-associated 
lymphoid tissue (MALT lymphoma)
Primary Cutaneous Marginal Zone 
B-cell Lymphoma (PCMZL)
Centroblastic/ centrocytic or 
centroblastic lymphoma
Primary cutaneous follicle 
centre cell lymphoma
Cutaneous follicle centre lymphoma*
Diffuse large B-cell lymphoma#




Primary cutaneous large B-cell 
lymphoma of the leg
Diffuse large B-cell lymphoma Primary Cutaneous diffuse Large 
B-cell Lymphoma, Leg Type 
(PCLBCL, LT)
* Cases with a (partly) follicular growth pattern
# Cases with a diffuse growth pattern
Outstanding issues
At the time the WHO-EORTC classification was published, there were still several 
outstanding issues requiring additional study. 
First, the definitions of PCFCL and PCLBCL, LT in the WHO-EORTC 
classification imply that differentiation between PCFCL and PCLBCL, LT is determined 
above all by morphological criteria, namely the absence or presence of confluent sheets of 
centroblasts and/or immunoblasts (designated previously as cleaved cell versus round cell 
morphology46) and no longer by site (non-leg versus leg) as in the EORTC 
classification.1;9;48 This implies that a proportion of patients classified as PCFCCL or 
PCLBCL-leg in the EORTC classification will be assigned to another prognostic category, 
which may have important therapeutic consequences. Recent studies suggest that this 
concerns 10-15% of PCFCCL and PCLBCL-leg, but exact data are not available.49;50
Second, recent studies also illustrated that the interpretation of the group of 
PCLBCL, other is defined in different ways. Some authors exclude rare Bcl-2 negative 
cases from the group of PCLBCL, LT and include them in the heterogeneous group of 
PCLBCL, other49, whereas others include all cases with characteristic round-cell 
morphological features within the group of PCLBCL, LT, irrespective of Bcl-2 
expression.50
Third, previous studies have suggested several clinicopathologic and 
immunophenotypical parameters with prognostic significance in patients with CBCL.44;46;51-
54 The most interesting findings were that strong expression of Bcl-2 is associated with an 
unfavorable prognosis in PCFCL cases with a diffuse growth pattern44 and that inactivation 
of CDKN2A is a negative prognostic predictor in PCLBCL, LT patients.55 However, most 
of these studies were based on cases classified according to older classifications systems, 
on mixed groups of patients or, as in the latter study, on only a small number of patients.
18
Therefore, in the study described in Chapter 2 we reviewed clinical data and 
histologic sections of 300 CBCL patients included in the database of the Dutch Cutaneous 
Lymphoma Group (DCLG) who were originally classified by the EORTC classification, 
and reclassified all cases according to the criteria of the WHO-EORTC classification as 
well as those of the WHO classification. The aims were to (1) assess the clinical 
significance of this new classification; (2) determine the percentage of CBCL patients 
assigned to a different prognostic category when compared with the EORTC and WHO 
schemes; (3) define more precisely the clinicopathologic features and prognostic factor of 
the newly defined categories; and (4) establish more clearly which cases should be assigned 
to the group of PCLBCL, other. 
In addition, in Chapter 3 we aimed to confirm inactivation of CDKN2A as a 
prognostic marker for the group of PCLBCL, LT on a larger patient group. This study 
describes the results of an European multicenter study, conducted within the framework of 
the EORTC-CLG. 
Staging of cutaneous B-cell lymphomas
The TNM classification system for primary cutaneous lymphomas other than mycosis 
fungoides and Sézary Syndrome 
Staging of cancer is important in the appropriate and effective care of patients. The 
goals of a staging system for cutaneous lymphoma are to offer a clinically reasonable basis 
for appropriate management, to predict prognosis, and to facilitate comparison of results 
among different therapies and different institutions. The most widely used staging system 
for lymphoma is the Ann Arbor system, which was first introduced as a staging system for 
Hodgkin lymphoma in 1971.56;57 Although its utility for the staging of other lymphomas has 
been challenged, it is still the primary means for classifying patients with non-Hodgkin 
lymphomas (NHL).58 The Ann Arbor system is primarily an anatomical assessment of 
disease with modifications by presence or absence of systemic symptoms. However, it does 
not distinguish consistently between patients with different prognoses. Thus, in 1993, the 
International Prognostic Index was established to supplement the Ann Arbor staging to aid 
in the treatment decision or stratification of patients in clinical trials for patients with 
lymphoma.59 However, the Ann Arbor system has a number of shortcomings, especially 
when staging lymphomas that arise primarily in extranodal sites such as the skin. In 
primary cutaneous lymphomas, the initial stage according to the Ann Arbor system would 
either be IE (if single skin site) or IVD + (if multiple skin sites), thus disproportionately or 
inappropriately placing high number of patients in the highest stage, resulting in 
unnecessarily aggressive treatments. 
The TNM classification system is the most widely used means for classifying the 
extent of nonlymphoid malignant disease. An adjusted TNM + B (blood) system has been 
in use for nearly 30 years to stage patients with mycosis fungoides (MF) and Sézary 
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syndrome (SS), both forms of CTCL60, and this system has recently been revised and 
updated.61 However, this system is not appropriate for staging of other forms of primary 
cutaneous lymphomas. Therefore, representatives of the International Society for 
Cutaneous Lymphomas (ISCL) and EORTC-CLG recently published a consensus proposal 
for a TNM classification system applicable to all types of primary cutaneous lymphomas 
other than MF/SS.62 This proposed TNM system is primarily meant to document extent of 
disease in a consistent matter, thereby facilitating comparison of studies at different 
institutes. Studies investigating the applicability of this TNM system on a group of CBCL 
have not been performed. Moreover, the prognostic significance of this proposed system for 
CBCL was unknown. In the study described in Chapter 4 we therefore tested its clinical 
applicability on the large group of CBCL which were reclassified according to the WHO-
EORTC classification as described in Chapter 2, and evaluated its prognostic relevance for 
the group of CBCL. In addition, these results were compared with the scoring of disease 
extent as used by the Dutch Cutaneous Lymphoma Group (DCLG) since many years.    
Bone marrow examination in the staging of cutaneous B-cell lymphomas
Ever since the first introduction of a separate classification for primary cutaneous 
lymphomas, it was recognized that a diagnosis of true primary cutaneous lymphoma can 
only be made after adequate staging investigations have been performed. These include a 
thorough physical examination, laboratory studies, imaging techniques and a bone marrow 
biopsy (BMB). However, in the paper introducing the TNM staging system for primary 
cutaneous lymphomas other than MF and SS, described previously62, it was for the first 
time suggested that bone marrow examination was recommended, but not required in 
indolent types of primary cutaneous lymphoma, including PCMZL and PCFCL. However, 
in most clinical practice guidelines for NHL, unilateral trephine BMB are part of the routine 
work-up in all patients with (a suspicion of) NHL. Moreover, the recommendation that a 
BMB is not required in indolent types of CBCL is confusing, as studies describing these 
PCMZL and PCFCL as indolent lymphomas, required negative staging procedures, 
including a negative BMB.3
Studies on the frequency of bone marrow involvement in this specific group of 
patients have never been performed. In the study described in Chapter 5 we evaluated the 
frequency of bone marrow involvement in a large group of patients with histological skin 
features consistent with a marginal zone lymphoma (MZL) or follicle centre lymphoma 
(FCL), in order to determine whether our current policy to perform a BMB in all patients 
with a histological diagnosis of cutaneous MZL or FCL should be maintained. 
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Treatment of primary cutaneous B-cell lymphomas 
It is generally recognized that PCMZL and PCFCL are indolent types of CBCL, which 
should not be treated primarily with systemic chemotherapy, and that PCLBCL, LT is 
characterized by a more unfavourable prognosis, justifying more aggressive therapeutic 
approaches. In recent years various new therapies for the treatment of CBCL, like rituximab 
and interferon alpha, have become available, supplementing traditional therapies like, 
surgical excision, local radiotherapy (RT), systemic multiagent chemotherapy or 
combinations of the latter two. However, the most appropriate therapy for each of the 
newly defined entities remains to be determined. 
RT is the most widely applied and best known treatment in CBCL. Already in 
1951 Crosti described seven cases of “reticulohistiocytoma of the dorsum” that were 
markedly sensitive to radiation therapy.63 This entity is nowadays classified as PCFCL. 
Previous studies have shown that RT is a suitable treatment for both PCFCL as well as 
PCMZL, and perhaps also for  PCLBCL, LT presenting with solitary or localized skin 
lesions.23;41;42;64;65 However, data from the literature regarding efficacy and relapse rate 
show a wide variation.41;42;64;66-69 Moreover, these studies are all based on cases classified 
according to the EORTC or WHO schemes, and it might be expected that a number of cases 
would be assigned to a different prognostic category, using the WHO-EORTC 
classification. These observations prompted us to evaluate the results of RT as initial 
treatment in a large group of CBCL classified according to the WHO-EORTC 
classification. The aim of this study, described in Chapter 6, was to define remission, 
relapse and survival rates of these newly defined groups after treatment with RT, and to 
establish for which patients this is a safe and effective treatment. 
In summary, with the advent of the WHO-EORTC consensus classification for 
cutaneous lymphomas in 2005, uniform terminology and classification for this rare group of 
neoplasms was introduced. However, staging procedures and treatment strategies still 
varied between different cutaneous lymphoma centres, which may be due to the fact that 
consensus recommendations for the management of CBCL have never been published. 
Following the results of Chapters 4-6 and based on an extensive literature review and 
discussions among experts in the field of cutaneous lymphoma, collaborating in the 
EORTC-CLG and the ISCL, we formulated consensus recommendations for the 
management of the three main groups of CBCL, which are described in Chapter 7.
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Aims and outline of the thesis
The studies presented in this thesis have aimed to address outstanding questions regarding 
the classification, prognostication, staging and treatment of CBCL.
Chapter 2 investigates the clinical applicability of the WHO-EORTC 
classification on a group of 300 patients with CBCL and determined the percentage of 
patients that was assigned to a different prognostic category using this classification as 
compared to the previously used EORTC and WHO classifications. Furthermore, 
clinicopathologic features and prognostic markers for the new WHO-EORTC categories 
and more precise criteria for the group of PCLBCL, other are defined.
Chapter 3 investigates if previously reported findings of inactivation of the 
CDKN2A gene as a prognostic marker can be confirmed on a large group of PCLBCL, LT 
and aims to further fine-map the aberrations found in this region by using MLPA. 
Chapter 4 evaluates the clinical applicability and prognostic significance of the 
newly proposed TNM classification system for primary cutaneous lymphomas other than 
MF and SS on a group of 300 CBCL patients classified according to the new WHO-
EORTC criteria and in addition, compares this classification system with the system used 
by the Dutch Cutaneous Lymphoma Group.
Chapter 5 investigates the frequency of bone marrow involvement in patients 
presenting with skin lesions that show histological features suggesting an indolent type of 
cutaneous B-cell lymphoma and evaluates whether the current practice to perform bone 
marrow biopsies in all these patients should be maintained.
Chapter 6 retrospectively analyzes the results of radiotherapy in a large group of 
CBCL classified according to the WHO-EORTC classification and establishes for which 
groups of patients this is a safe and effective treatment.
Chapter 7 provides a review concerning consensus recommendations for the 
management of CBCL, which were based on an extensive literature study and discussions 
among a broad panel of dermatologists, haematologists and (radiation) oncologists involved 
in the treatment of CBCL patients.
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PURPOSE: In the new WHO-EORTC classification for cutaneous lymphomas three major 
groups of primary cutaneous B-cell lymphoma (CBCL) are distinguished: primary 
cutaneous marginal zone B-cell lymphoma (PCMZL) and primary cutaneous follicle center 
lymphoma (PCFCL) with a good prognosis, and primary cutaneous large B-cell lymphoma, 
leg type (PCLBCL, LT) with an intermediate prognosis. This study aimed to assess the 
clinical significance of the new classification as compared to previous classification 
schemes (EORTC 1997; WHO 2001) and to define prognostic factors within the newly 
defined categories.
PATIENTS AND METHODS: In the present study clinical data and histological sections 
of 300 CBCL formerly classified according to the EORTC classification were reviewed and 
reclassified according to the WHO and the new WHO-EORTC classification schemes.
RESULTS: After reclassification the study comprised 71 PCMZL, 171 PCFCL and 58 
PCLBCL, LT showing 5-year disease specific survivals of 98%, 95% and 50%, 
respectively. As compared with the EORTC and WHO schemes 5.3% and 36.3% of CBCL 
were reclassified into another prognostic category. Multivariate analysis of PCFCL 
revealed localization on the leg and expression of FOXP1 as independent parameters 
associated with a poor prognosis. Expression of Bcl-2 or MUM-1 had no significant effect 
on survival in this group. In PCLBCL, LT no independent prognostic parameters were 
found. 
CONCLUSIONS: These results emphasize the clinical significance of the WHO-EORTC 
classification, but suggest that within the group of PCFCL distinction should be made 
between cases presenting on the legs and cases presenting at other sites. 
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Introduction
In recent years, there has been considerable debate regarding the classification and 
terminology of the group of primary cutaneous B-cell lymphomas (CBCL).1-4 This 
controversy, which resulted from differences between the EORTC and WHO schemes in 
the classification of CBCL, may have come to an end with the recent introduction of the 
new WHO-EORTC classification for cutaneous lymphomas.5-8 In this new classification, 
three main types of CBCL are recognized: primary cutaneous marginal zone B-cell 
lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL) and primary 
cutaneous large B-cell lymphoma, leg type (PCLBCL, LT). In addition, it contains a 
category called primary cutaneous large B-cell lymphoma, other (PCLBCL, other) for 
diffuse large B-cell lymphomas, which do not fit in the group of PCLBCL, LT or the group 
of PCFCL with a diffuse infiltration of large centrocytes.
PCFCL is defined as a tumor of neoplastic follicle center cells, which may show a 
follicular, a follicular and diffuse or diffuse growth pattern, and which is predominantly 
composed of generally large centrocytes (large cleaved cells). In most cases the tumor cells 
do not express Bcl-2 and MUM-1. PCLBCL, LT is defined by a predominance or confluent 
sheets of medium-sized to large B-cells with round nuclei resembling centroblasts and/or 
immunoblasts, which generally show strong expression of Bcl-2 and MUM-1. These 
definitions imply that differentiation between PCFCL and PCLBCL, LT is determined 
above all by morphological criteria, namely the absence or presence of confluent sheets of 
centroblasts and/or immunoblasts (designated previously as cleaved cell versus round cell 
morphology9) and no longer by site (non-leg versus leg) as in the EORTC 
classification.7;10;11 This implies that a proportion of patients classified as primary 
cutaneous follicle center cell lymphoma (PCFCCL) or primary cutaneous large B-cell 
lymphoma of the leg (PCLBCL, leg) in the EORTC classification will be assigned to 
another prognostic category, which may have important therapeutic consequences. Recent 
studies suggest that this concerns 10-15% of PCFCCL and PCLBCL, leg, but exact data are 
not available. 12;13These studies also illustrate that the definition of the group of PCLBCL, 
other leaves room for different interpretations. 
In the present study clinical data and histologic sections of 300 CBCL included in the 
registry of the Dutch Cutaneous Lymphoma Group and originally classified by the EORTC 
classification, were reviewed and reclassified by the new WHO-EORTC classification as 
well as by the WHO classification. The aims of this study were: 1. to assess the clinical 
significance of this new classification; 2. to determine the percentage of CBCL patients 
assigned to a different prognostic category as compared to the EORTC and WHO schemes; 
3. to define more precisely the clinicopathologic features and prognostic factors of the 
newly defined WHO-EORTC categories; 4. to establish whether PCLBCL, LT not 





Between 1985 and 2005, 320 CBCL, including 72 PCMZL/ PCI (primary cutaneous 
immunocytomas), 185 PCFCCL and 63 PCLBCL, leg, had been included in the registry of 
the Dutch Cutaneous Lymphoma Group. All cases had been classified by an expert panel of 
dermatologists and pathologists at the time of diagnosis using the criteria of the EORTC 
classification.
In all cases, the presence of extracutaneous disease at the time of diagnosis had been 
excluded by standard staging procedures including computerized tomography of thorax and 
abdomen, and bone marrow cytology and histology. Follow-up data had been collected 
yearly for each patient. 
Histological review
For each case, hematoxylin-eosin stained sections, routine immunostainings and paraffin 
blocks were collected from the archives of the participating or referring departments. If 
paraffin blocks were available, additional stainings for Bcl-2, Bcl-6, Ki-67 (Dako, Glostrup, 
Denmark), CD10 and CD35 (Novocastra, Newcastle upon Tyne, United Kingdom) and in 
cases of PCFCCL and PCLBCL, leg also for MUM-1 (Dako, Glostrup, Denmark) and 
FOXP1 (kindly provided by Dr. A. Banham, Nuffield Department of Clinical and 
Laboratory Sciences, Oxford, United Kingdom) was performed, using standard techniques 
described previously.14;15
Bcl-2, Bcl-6 and CD10 staining was considered positive if more than 50% of the neoplastic 
B-cells showed an unequivocal positive staining.12;16;17 In case of CD10, only a 
membranous staining pattern on the tumor cells was considered positive. For expression of 
MUM-1, nuclear staining of more than 30% of the neoplastic B-cells was considered 
positive.18;19 Consistent with prior studies12;20 FOXP1 was scored into 3 groups: positive (> 
90% strongly positive cells), weak (20-90% weakly-moderately positive cells) and negative 
(< 20% weakly stained cells). 
From the initial group of 320 patients 10 patients were excluded because of incomplete 
clinical details or lack of follow-up. Another 10 cases were excluded because histological 
sections were either not available or of insufficient quality to allow proper reclassification. 
The final study group comprised 300 CBCL including 71 PCMZL, 169 PCFCCL and 60 
PCLBCL, leg (see Table 1). These 300 cases were reclassified as PCMZL, PCFCL or 
PCLBCL, LT following the WHO-EORTC classification, and as extranodal marginal zone 
B-cell lymphoma (EMZL), cutaneous follicle center lymphoma (cFCL) or diffuse large B-
cell lymphoma (DLBCL) using the WHO classification.
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Statistical analysis
All statistical calculations were performed using SPSS 12.0.1 (SPSS Inc, Chicago, IL). 
Overall survival (OS) was calculated from the date of diagnosis until the patient’s death or 
date of last follow-up. Disease specific survival (DSS) was calculated from the date of 
diagnosis until death due to lymphoma or date of last follow-up. Survival curves were 
estimated by the method of Kaplan and Meier and statistical comparison between curves 
was done by log-rank testing. Prognostic factors within the different entities were evaluated 
by univariate and multivariate analysis with OS and DSS as endpoints and p values below 
0.05 were considered significant. Parameters included for univariate analysis were: age (≤ 
70 vs. > 70 years), gender, localization of skin lesions (leg vs. non-leg), extent (solitary vs. 
localized vs. multifocal), growth pattern (only in PCFCL: follicular vs. follicular-diffuse vs. 
diffuse), Bcl-2 (positive vs. negative), MUM-1 (positive vs. negative), FOXP1 (positive vs. 
weak vs. negative). Multivariate analysis was performed with the use of a Cox proportional 
hazards regression model with a stepwise selection of the significant variables. Multivariate 
analysis was stratified for age. All other parameters included in the univariate analysis were 
introduced in the multivariate analysis and all parameters were categorical. 
Results
Comparison between the EORTC, the WHO and the WHO-EORTC classification
This is the first study which allows direct comparison of the clinical significance of the 
EORTC7, the WHO5;7 and the WHO-EORTC6;8 classification for the group of CBCL. The 
number of cases reclassified into another prognostic category are presented in Table 1 
(EORTC versus WHO-EORTC) and Table 2 (WHO versus WHO-EORTC). 
All 71 PCMZL/PCI in the EORTC classification were classified as EMZL in the WHO 
classification and as PCMZL using the criteria of the WHO-EORTC classification (Tables 
1 and 2). 
Of the 169 cases classified as PCFCCL in the EORTC classification, 62 cases showing a 
follicular (four cases; 2.4%) or a follicular and diffuse (58 cases; 34.3%) growth pattern, 
were classified as cFCL, while 107 cases (63.3%) showing a diffuse population of large 
centrocytes were classified as DLBCL using the WHO classification (Table 2). Following 
the WHO-EORTC classification the large majority of PCFCCL (162 of 169 cases: 95.9%) 
was reclassified as PCFCL. The remaining seven PCFCCL showing a predominance or 
confluent sheets of cells with a centroblast- or immunoblasts-like morphology were 
reclassified as PCLBCL, LT. 
All 60 cases classified as PCLBCL, leg by the EORTC scheme were classified as DLBCL 
in the WHO classification. Fifty-one of 60 cases showed diffuse infiltrates of centroblasts 
and/or immunoblasts and were therefore classified as PCLBCL, LT following the WHO-
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EORTC classification (Table 1). Nine of 60 cases (15.0%) showed diffuse infiltrates 
predominantly composed of large cleaved cells, in the absence of sheets or clusters of 
centroblasts and/or immunoblasts, and were therefore classified as PCFCL. 
 The 5-year OS for the three main types of CBCL according to the EORTC, WHO and 
WHO-EORTC classifications are presented in Figure 1. 
Table 1. 
Classification of 300 CBCL: comparison between the EORTC classification and the WHO-EORTC classification. 
EORTC No WHO-EORTC No
Primary cutaneous 
marginal zone B-cell 
lymphoma 
71 Primary cutaneous marginal 
zone B-cell lymphoma
71
Primary cutaneous follicle 
center cell lymphoma           
169 Primary cutaneous follicle 
center lymphoma 
Primary cutaneous large B-
cell lymphoma, leg type                         
162
7 
Primary cutaneous large B-
cell lymphoma, leg
60 Primary cutaneous follicle 
center lymphoma
Primary cutaneous large B-
cell lymphoma, leg type
9  
51
16 of 300 cases (5,3%) were reclassified into another prognostic category (indicated in bold).
Table 2. 
Classification of 300 CBCL: comparison between the WHO 
classification and the WHO-EORTC classification. 
WHO No WHO-EORTC No
Extranodal marginal zone 
B-cell lymphoma 
71 Primary cutaneous marginal 
zone B-cell lymphoma
71
Cutaneous follicle center 
lymphoma           
62 Primary cutaneous follicle 
center lymphoma                          
62
Diffuse large B-cell 
lymphoma
167 Primary cutaneous follicle 
center lymphoma
Primary cutaneous large B-
cell lymphoma, leg type
109 
58
109 of 300 cases (36,3%) were reclassified into another prognostic category (indicated in bold).
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Figure 1. Overall survival of 300 CBCL classified according to the criteria of the EORTC 
classification (A), the WHO classification (B) and the WHO-EORTC classification (C).
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Clinical features and prognostic parameters of the WHO-EORTC groups
After reclassification, the study group contained 71 PCMZL, 171 PCFCL and 58 PCLBCL, 
LT. The main clinical characteristics and follow-up data are presented in Table 3. In the 
following section relevant clinicopathologic and immunophenotypical data and their 
prognostic significance are presented.
PCMZL
Follow-up data of the 71 PCMZL showed development of extracutaneous disease in six of 
71 (8.5%) cases, and overall and disease specific 5-year-survivals of 94% and 98%, 
respectively (Table 3). The clinicopathologic details of 50 of these 71 patients have been 
reported recently, and will therefore no further be discussed.21
PCFCL
This group contained 171 cases, including nine cases classified previously as PCLBCL, leg. 
Characteristically, most patients presented with localized lesions on the head (37.4%) or 
trunk (39.2%); 11 cases (5.8%) presented with skin lesions on the leg(s). 
Histologically, a follicular, a follicular and diffuse or diffuse growth pattern was observed 
in 2.3% (4/171), 33.9% (58/171), and 63.7% (109/171) of cases.    
Expression of Bcl-2 by more than 50% of the neoplastic B-cells was observed in 16 of 148 
(10.8%) cases and expression of MUM-1 by more than 30% of the neoplastic B-cells in 13 
of 128 (10.2%) cases (Table 4). Strong nuclear expression of FOXP1 was observed in only 
four of 104 (3.8%) cases. Bcl-6 and CD10 were expressed by 122 of 132 (92.4%) and 9 of 
141 (6.0%) cases. CD10 expression was found in seven of 48 (14.6%) PCFCL with a 
follicular or follicular and diffuse growth pattern, and in only two of 93 (2.2%) PCFCL 
with a diffuse growth pattern. After a median follow-up period of 62 months (range, 2 –
336 month), 18 of 171 developed extracutaneous disease, and nine patients died of 
lymphoma, four of whom due to central nervous system involvement. The overall and 
disease specific 5-year survivals were 87% and 95%, respectively. 
Prognostic factors
Univariate analysis of OS on the total group of PCFCL (n = 171) showed that the following 
variables were related to a shorter survival: age (p < 0.0001), female gender (p = 0.028), 
localization on the leg(s) (p < 0.0001), extent of skin lesions (p = 0.045) and expression of 
FOXP1 (p = 0.002). Growth pattern, expression of Bcl-2 or MUM-1 had no significant 
effect on OS. In multivariate analysis, only localization on the leg(s) (p = 0.001) and 
expression of FOXP1 (p = 0.033) remained significant independent factors associated with 
a poor prognosis. Both weak and positive expression of FOXP1 was associated with 
inferior prognosis as compared to the negative cases. PCFCL presenting with skin lesions 
on the leg(s) developed extracutaneous disease in five of 11 cases (46%) and had a 5-year 
OS and DSS of 22% and 41%, respectively, whereas PCFCL presenting at other sites than 
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the leg developed extracutaneous disease in 13 of 160 cases (8%) and showed 5-year OS 
and DSS of 92% and 98%, respectively (Figure 2). Multivariate analysis of OS in only 
those PCFCL with a diffuse infiltrate of large centrocytes (n = 109) revealed localization on 
the leg as the only independent parameter significantly related with a poor survival (p = 
0.006). 
PCLBCL, leg type
This group contained 58 cases, including seven cases classified previously as PCFCCL 
using the EORTC classification. Consistently, most cases presented with skin lesions on 
one (40 cases) or both legs (six cases) or with lesions on the leg(s) and other skin site(s) 
(five cases); seven patients had presented with skin lesions restricted to sites other than the 
leg. 
Characteristically, the neoplastic B-cells strongly expressed Bcl-2 (44 of 49 cases; 89.8%), 
MUM-1 (36 of 40 cases; 90.0%) and FOXP1 (26 of 32 cases; 81.3%).  Bcl-6 and CD10 
were expressed in 30 of 44 (68.2%) and zero of 47 (0%) cases, respectively (Table 4).
After a median follow-up of 26 months (range 2 – 276 months), 27 of 58 cases had 
developed extracutaneous disease and 26 of 58 cases had died of lymphoma. The overall 
and disease specific 5-year-survivals were 37% and 50%, respectively.
Prognostic factors
In univariate analysis of OS only age (p = 0.041) and extent of skin lesions (p = 0.023) 
were associated with a poor prognosis. The 5-year OS for patients presenting with a solitary 
tumor was 70% as compared to 27% and 0% for patients presenting with localized or 
multifocal disease respectively. Gender, localization on the leg, expression of Bcl-2, MUM-
1 and FOXP1 had no prognostic significance in this group. In multivariate analysis, no 
independent prognostic factors were found. Importantly, no differences in survival were 
found between PCLBCL, LT presenting on the leg(s) and PCLBCL, LT presenting at sites 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this study histological sections of 300 Dutch CBCL patients, formerly classified 
according to the EORTC classification7, were reviewed and classified according to the 
WHO5 and the new WHO-EORTC classification.6;8 Using the criteria of the WHO-EORTC 
classification PCMZL and PCFCL showed 5-year DSS of 98% and 95%, respectively, 
whereas PCLBCL, LT had a 5-year DSS of 50%. These results are in agreement with the 
results of recent studies and confirm that the new WHO-EORTC classification adequately 
distinguishes between CBCL with an indolent and CBCL with a more aggressive clinical 
behavior.3;12;13
Comparison between the three classification schemes showed no other than semantic 
differences in the classification of PCMZL and PCFCL with a follicular or follicular and 
diffuse growth pattern. However, with respect to CBCL with a diffuse population of large 
neoplastic B-cells 16 of 167 (9.6%) and 109 of 167 (65.3%) cases, classified according to 
the EORTC and WHO classification, respectively, were reclassified in another prognostic 
category.  Seven cases originally classified as PCFCCL in the EORTC classification, were 
reclassified as PCLBCL, LT, because of the presence of confluent sheets of cells with a 
centroblast- or immunoblast-like morphology. Conversely, nine cases originally classified 
as PCLBCL, leg, showed diffuse infiltrates of large cleaved cells and were therefore 
reclassified as PCFCL. As compared to the WHO classification, 109 of 167 cases (65%) 
classified as DLBCL were reclassified as PCFCL, which implies that these patients should 
be treated primarily with radiotherapy rather than with multi-agent chemotherapy.22-27
Taken together, these results illustrate that the WHO-EORTC classification is a major step 
forward, and may contribute to more appropriate treatment in patients with CBCL. 
A second goal of the present study was to define prognostic parameters within the redefined
categories PCFCL and PCLBCL, LT. Both in the total group of PCFCL and in the group of 
PCFCL with a diffuse infiltrate of large cleaved cells, site of clinical presentation appeared 





Positive (%) 16/148 (11%) 13/140 (9%) 3/8 (38%) 44/49 (93%) 40/43 (93%) 4/6 (67%)
MUM-1 





4/104   (4%)
25/104 (24%)
75/104 (72%)







5/32   (16%)
1/32   (3%)
23/29 (79%)
5/29   (17%)





Positive (%) 122/132 (92%) 118/126 (94%) 4/6 (67%) 30/44 (68%) 26/39 (67%) 4/5 (80%)
CD10
Positive (%) 9/141 (6%) 9/133 (7%) 0/8 (0%) 0/47 (0%) 0/42 (0%) 0/5 (0%)
Table 4. Expression patterns in PCFCL, PCLBCL, LT and subgroups
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the most important independent prognostic factor. Consistent with previous studies, PCFCL 
presenting on the leg had a much worse prognosis than PCFCL presenting at other sites, but 
similar to PCLBCL, LT9;12 (see Figure 2).We therefore suggest that within the group of 
PCFCL further distinction should be made on the basis of site to prevent undertreatment of 
patients presenting with skin lesions on the leg. Expression of Bcl-2 and MUM-1 were no 
independent prognostic parameters, neither in the total group of PCFCL, nor in PCFCL 
with a diffuse infiltrate of large cleaved cells.
In the group of PCLBCL, LT the extent of skin lesions at the time of diagnosis and age 
were the only prognostic parameters. Comparison of Bcl-2 positive and Bcl-2 negative 
PCLBCL, LT showed no significant difference in 5-year DSS (47% versus 60%, p = 0.512) 
or 5-year OS (38 % versus 40%, p = 0.579), which is consistent with the results of Kodama 
et al.12 Similarly, in both studies no significant differences in 5-year OS and DSS were 
found between PCLBCL, LT with or without expression of MUM-1 or FOXP1. These data 
indicate that distinction between cases with or without expression of Bcl-2, MUM-1 or 
FOXP1 is not useful, and that categorization of Bcl-2 negative cases as PCLBCL, other is 
not justified.12 We therefore propose that this term should only be used for exceptional 
cases of CBCL that do not fit the criteria of PCFCL or PCLBCL, LT, such as rare cases of 
intravascular large B-cell lymphoma, T-cell/histiocyte-rich B-cell lymphoma or 
plasmablastic lymphoma with only skin lesions at presentation.
In the WHO-EORTC classification, differentiation between PCFCL with a diffuse large 
cell infiltrate and PCLBCL, LT has become more difficult, since it is based primarily on 
cell morphology (cleaved versus round) and no longer on the basis of site (non-leg versus 
leg), as in the EORTC classification. Classification on the basis of morphology may be 
difficult and is associated with a considerable inter-observer variation.9 In such difficult 
cases, the presence of a considerable proportion of admixed T-cells, the presence of a 
stromal reaction as well as demonstration of (remnants of) follicular dendritic cells
networks by staining with appropriate antibodies (CD35 or CD21) may serve as useful 
additional criteria suggesting a diagnosis of PCFCL. Moreover, since PCLBCL, LT, unlike 
PCFCL, characteristically shows strong expression of Bcl-2, MUM-1 and FOXP1, this 
phenotypic profile might also be a useful adjunct, supporting a diagnosis of PCLBCL, LT. 
However, since Bcl-2, MUM-1 and to a lesser extent FOXP1 are also expressed by a small 
minority of PCFCL, these markers can not be used as a golden standard to differentiate 
between both conditions (Table 4).
         
In conclusion, the results of this study emphasize the clinical significance of the new WHO-
EORTC classification and suggest that it may contribute to better diagnosis and treatment. 
Reclassification of PCFCCL (EORTC) with a predominant round cell morphology as 
PCLBCL, LT proved clinically relevant, which implies that such cases should be treated 
primarily with multi-agent chemotherapy. However, reclassification of PCLBCL, leg 
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(EORTC) with a predominant cleaved cell morphology into the group of indolent PCFCL 
proved less fortunate, since these cases have a much worse prognosis than PCFCL not 
presenting on the leg and should not be treated routinely with radiotherapy. Consistent with 
the results of a previous European multicenter study9,  we suggest that in addition to the 
WHO-EORTC classification also site of presentation is taken into account to select the 
most appropriate treatment in patients with PCFCL. 
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Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT) is the most 
aggressive type of primary cutaneous B-cell lymphoma. In a recent study on 12 patients it 
was found that inactivation of CDKN2A by either deletion of 9p21.3 or promoter 
hypermethylation is correlated with a worse prognosis. 
In the present EORTC multi-centre study, skin biopsies of 64 PCLBCL, LT patients were 
analyzed by Multiplex Ligation-dependent Probe Amplification to validate these previous 
results and to fine-map the losses in this region. Although no minimal common region of 
loss could be identified, most homozygous loss was observed in the CDKN2A gene (43/64; 
67%) encoding p16 and p14ARF. Promoter hypermethylation of p16 and p14/ARF was 
found in six and zero cases respectively.  Survival was markedly different between patients 
with versus without aberrations in the CDKN2A gene (5-year disease-specific survival 43% 
versus 70%; p = 0.06). In conclusion, our results confirm that deletion of chromosome 
9p21.3 is found in a considerable proportion of PCLBCL, LT patients and that inactivation 
of the CDKN2A gene is associated with an unfavourable prognosis. In most patients the 




Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT) is the most 
aggressive type of primary cutaneous B-cell lymphoma (CBCL). It is generally 
characterized by rapidly growing tumours that present on the leg(s), but in a minority of 
patients skin lesions can also arise at other sites. Histologically it is defined as a tumour 
with a predominance or confluent sheets of large, atypical B-cells (resembling centroblasts 
and immunoblasts), which generally express Bcl-2 and MUM-1. The disease has an 
intermediate prognosis with a 5-year survival rate of only 50%.1 Since it is recognized that 
this disease represents a distinct type of CBCL, it will be included as a separate entity in the 
forthcoming WHO 2008 classification.
In a recent study by our group, using array-based comparative genomic hybridization 
(aCGH), it was found that inactivation of the CDKN2A region, encoding for the tumour 
suppressor genes p16 and p14ARF, by either deletion of chromosome 9p21.3 or promoter 
hypermethylation, is associated with a worse prognosis. However, these results were based 
on only 12 cases.2
Multiplex Ligation-dependent Probe Amplification (MLPA) has recently been described as 
a new method for relative quantification of multiple different DNA sequences in a single 
reaction, requiring only small amounts of DNA.3 Moreover, the application of this 
technique on DNA isolated from formalin-fixed, paraffin-embedded (FFPE) material has 
previously been reported to be reliable and less sensitive to DNA degradation.4-6 Targeted 
MLPA probe panels are commercially available including a set of probes targeting the 
chromosomal region of 9p21 containing several known genes (CDKN2A, coding for p16 
and p14ARF, CDKN2B, coding for p15 and MTAP). 
In the present study, MLPA was used to confirm that inactivation of CDKN2A is an 
unfavourable prognostic marker in a large patient group and to further fine-map the 9p21.3 
region in order to determine a possible minimal common region. 
Results
Testing the reliability of the MLPA technique
We first investigated whether results generated by MLPA were in accordance with our 
previous aCGH results.2 In addition, we aimed to obtain more information on the precise 
location of deletions as the MLPA technique has a much higher spatial resolution than the 
aCGH technique applied previously (see Figure 1).2 To that end, we subjected available 
isolated DNA from 12 patients (9 PCLBCL, LT and 3 primary cutaneous follicle centre 
lymphomas (PCFCL) previously investigated by aCGH to MLPA. We were indeed able to 
confirm chromosomal aberrations in 9p21.3 as detected by aCGH in all patients, with 
homozygous loss in four of 12 patients and hemizygous loss in two of 12 patients using 
MLPA (See Figure 2). Moreover, in three of the six patients that did not show loss in the 
aCGH analysis (three PCLBCL, LT and three PCFCL), MLPA allowed detection of 
hemizygous loss (and in one patient even homozygous loss) of individual probes within the 
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complete set (two PCLBCL, LT and one PCFCL) (see Figure 2). This demonstrates the 
higher sensitivity of the MLPA technique as compared to the aCGH platform previously 
used.  However, we could not detect a minimal common region of deletion within the 
CDKN2A gene region.
Since a considerable part of our samples was derived from FFPE material, it was 
felt important to test the claim that MLPA can be applied as reliably to DNA isolated from 
FFPE material as to DNA isolated from frozen material.6 To accomplish this, we analysed 
DNA from fresh-frozen samples and FFPE material taken simultaneously from the same 
tumour. This was done in two patients from whom at three different time points biopsy 
material was collected (primary tumour, first skin relapse and second skin relapse). We 
observed full concordance of the results as depicted for one patient in Figure 3, thereby 
demonstrating the applicability of this technique on partly degraded DNA. In addition, it 
was noted that the genetic lesions in the 9p21.3 region showed a stable pattern over time 
and did not alter with disease progression and treatment.
Figure 1. Schematical representation of 9p21.3 showing the spatial resolution of different 
techniques. 
MLPA can be used to fine-map the chromosomal aberrations as found by aCGH (BAC clone RP11-
149I2 corresponding to 21899259-22000413 (according to Ensembl) on  chr. 9) and FISH (e.g. LSI 
p16 probe from Vysis which, according to the manufacturer, at least includes the region from 
21792942 (D9S1749) - to 21995210 (D9S1752) on chromosome 9). Exact genomic positions of the 
MLPA probes can be requested at MRC Holland (info@mlpa.com).
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Figure 2. Array CGH vs. MLPA results for PCLBCL, LT (n = 9) and PCFCL patients (n = 3).
D+ = died of lymphoma, D- = died of other cause, A- = alive in complete remission. Black = 
homozygous loss, grey = hemizygous loss, white = no loss.
Allelic loss at the 9p21.3 locus
Having confirmed that MLPA can reliably detect genetic lesions in frozen as well as in 
FFPE material, we subjected the whole study group to MLPA. In total, tumour biopsies 
from 64 patients with a diagnosis of PCLBCL, LT were included in the final study group. 
This included the nine patients previously analyzed by aCGH and in addition 55 new 
patients. The overall MLPA results for these patients are depicted in Figure 4. It was found 
that 45 patients (70%) showed homozygous loss of one or multiple probes within the 
9p21.3 region. Hemizygous loss was found in 14 patients and five patients did not show 
any detectable loss in this region. 
Most chromosomal aberrations were localized in the CDKN2A gene. 
Homozygous loss within this region was found in 43/64 cases (67%). Homozygous losses 
in the coding regions for p16 (exon 1α, 2 and 3) and p14ARF (exon 1β and 2), as well as 
both promoter regions, were found in 40/64 (63%) and 37/64 (58%) cases respectively. 
Specific probes, most often lost were located in exon 1 coding for p16 and exon 2 coding 
for both p16 and p14ARF (both probes were lost in 31/64 cases; 48%). In most patients 
however, the deletion covered a large part of chromosome 9p21.3 instead of a smaller 
minimal common region (see Figure 4).
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Analysis of p16 and p14ARF promoter methylation status
From 20/21 patients without homozygous loss in CDKN2A, sufficient DNA was available 
to determine the promoter methylation status of p16 and p14ARF. In none of the samples 
methylation of the p14ARF promoter was found. However, methylation of the p16 
promoter was detected in 6/20 samples. Five of these samples showed hemizygous loss 
within the p16 coding and promoter region in MLPA analysis and one sample had no loss 
within this region. 
Figure 3. MLPA results for DNA from fresh frozen (black bars) versus FFPE material (grey 
bars) from one patient.
Skin biopsies obtained at diagnosis (A), at first skin relapse after 32 months (B) and at second skin 
relapse after 39 months (C). FR: flanking region
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Figure 4. Total MLPA results for 64 PCLBCL, LT patients.
Black = homozygous loss (ratio < 0.4), grey = hemizygous loss (ratio between 0.4 and 0.7), white = 
no loss (ratio > 0.7). FR: flanking region
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Correlation with survival
Survival analysis revealed a clear correlation between homozygous loss in chromosome 
9p21.3 and reduced survival. Patients without homozygous loss in this region had an 
actuarial 5-year disease-specific survival (DSS) of 68%, while patients with loss of at least 
one probe in this region had a 5-year DSS of 39% (p = 0.06). Although statistically not 
significant, these results are in line with the findings described by Dijkman et al.9 Since 
most loss occurred in the CDKN2A region, we also performed survival analysis for losses 
specific to this region and in addition also for loss in areas coding specifically for p14ARF 
and p16 separately. Loss in the CDKN2A region was most strongly correlated with 
prognosis. Five-year DSS for patients with or without loss in this region was 38% versus 
69% (p = 0.03) (See Figure 5). Differences in 5-year DSS between patients with or without 
losses in the regions coding p14ARF or p16 were not or borderline significant, respectively. 
Finally, we tested whether inclusion of the methylation data affected the survival analysis. 
In the complete study group a total of 48 patients can be considered to have an inactivated 
CDKN2A gene (43 patients with homozygous loss in the CDKN2A gene and 5 patients 
with a methylated p16 promoter combined with hemizygous loss in CDKN2A). Five-year 
DSS for patients with and those without inactivation of CDKN2A are 70% and 43% 
respectively (p = 0,059)(See Figure 6).
Figure 5. Disease-specific survival of 64 PCLBCL, LT patients according to chromosomal 
aberrations within CDKN2A.
Solid line: patients with homozygous loss of one or multiple probes in CDKN2A (n = 43), dashed 
line: patients with no or hemizygous loss in CDKN2A (n = 21). Error bars indicate Standard Error.
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Figure 6. Disease-specific survival of 63 PCLBCL, LT patients according to CDKN2A status.
Solid line: patients with inactivation of  CDKN2A (n = 48), dashed line: patients without inactivation 
of CDKN2A (n = 15). In one patient no DNA was available for determining methylation status, this 
patient is not included in this analysis. Error bars indicate Standard Error.
Discussion
In this study we aimed to confirm recently reported data describing that loss of 9p21.3 and 
more specifically, inactivation of CDKN2A is commonly found and associated with 
inferior prognosis in PCLBCL, LT.2 By using MLPA we were able to confirm loss of 
9p21.3, including the CDKN2A gene, on a large group of patients with PCLBCL, LT. We 
observed full concordance with the results as obtained by aCGH, and, in addition, detected 
small areas of loss in three patients. So comparison between aCGH and MLPA confirms the 
higher sensitivity of the latter technique and its ability to fine-map larger areas of loss as 
found by genome-wide analyses such as aCGH using BAC clones as in the previous study. 
It was found that in most patients the deletion covers a substantial part (up to several tens of 
thousands of basepairs) of this chromosomal region. Although no minimal common region 
of loss could be detected, most chromosomal aberrations converged on the CDKN2A gene. 
An additional advantage of the MLPA technique is that it can be applied reliably on FFPE 
material of CBCL patients. Comparison between DNA derived from fresh-frozen and FFPE 
sections, obtained from the same tumour in two patients, showed identical results. 
Moreover, comparison of skin biopsy specimens obtained from consecutive tumours in 
these two patients, demonstrated identical chromosomal aberrations, indicating that these 
losses can display a stable pattern over time.
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Loss or inactivation of the CDKN2A gene either by deletion or promoter 
hypermethylation has been extensively reported in haematological malignancies, including 
B-cell non-Hodgkin lymphomas.7-10 CDKN2A codes for p16 and p14ARF, both of which 
are tumour suppressor genes and are negative regulators of cell cycle progression. In our 
study group, inactivation of CDKN2A was mostly due to (homozygous) deletion. Promoter 
hypermethylation of p16 was found in a minority of cases, which is in accordance with the 
results of previous studies in CBCL.11;12 Promoter hypermethylation of p14 was never 
detected. 
Besides confirming the loss in this chromosomal region we further wanted to 
validate the prognostic significance of the findings as reported previously. Although less 
striking than the results reported by Dijkman et al2, loss or inactivation of CDKN2A, was 
still associated with reduced survival (See Figures 5 and 6), which is also consistent with 
previous reports of others.11-13 Even though the results described herein show a clear, and 
borderline significant, correlation with reduced survival, loss of CDKN2A can not be used 
as the sole tool to optimize management in individual patients. 
In our study group there are several patients with deletions in 9p21.3, that have a favourable 
clinical course thus far. More importantly, five of 21 patients without inactivation of 
CDKN2A died of lymphoma 6-54 months (median 27 months) after diagnosis. Especially 
this latter group runs the risk of being undertreated when management would be solely 
based on CDKN2A status.
In conclusion, in a large part of PCLBCL, LT patients chromosomal loss is seen in 9p21.3. 
In most patients these losses are concentrated on the CDKN2A gene coding for p16 and 
p14ARF. Inactivation of this gene is caused by homozygous deletion or, less commonly, by 
promoter hypermethylation and is associated with a worse prognosis. However, caution is 
warranted before these results are incorporated into clinical decision making.
Material and Methods
Sample collection
Cases were collected from centres collaborating in the EORTC Cutaneous Lymphoma 
Group. Tumour DNA from pre-treatment skin biopsies of 80 patients were initially 
submitted for the study. Patients with incomplete staging investigations (minimum 
requirements being routine laboratory screening, CT scans of chest and abdomen and bone 
marrow biopsy) or follow-up of less than 12 months (unless caused by death due to 
lymphoma) were excluded from further analysis (n = 6). In addition, of all submitted cases 
H&E sections were reviewed for morphological reference and estimation of percentage 
tumour- and admixed reactive cells. In case of doubt about the percentage of tumour cells, 
we reviewed stainings for CD3 and CD20. If these were not available, the case was 
excluded. Combined with information on the expression of Bcl-2, MUM-1 and FOXP1, a 
diagnosis of PCLBCL, LT was confirmed or discarded. Cases in which a diagnosis of 
PCLBCL, LT could not be confirmed and cases with more than 30% admixed reactive T-
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cells were excluded (n = 5). Finally, five cases could not be analyzed due to poor quality 
DNA. The final study group consisted of 64 patients with a diagnosis of PCLBCL, LT. The 
study group contained 25 males and 39 females (male-female ratio: 0,6), with a median age 
at diagnosis of 78 years (range 47-92 years) and a median duration of follow-up of 34 
months (range 2-158 months). Clinical characteristics and treatment data are presented in 
Table 1. In addition, 3 patients with a diagnosis of primary cutaneous follicle centre 
lymphoma (PCFCL) were included in the experiment validating the MLPA technique. 
Twelve of the above described patients (9 PCLBCL, LT and 3 PCFCL) were formerly 
analyzed with aCGH.2 Genomic DNA was extracted from either fresh frozen material, or 
FFPE sections, using local protocols. 
Table 1. Clinical and treatment characteristics of 64 patients with PCLBCL, LT.
Total number of patients 64
Age, years


























































Fine-mapping chromosomal loss at 9p21.3 using MLPA
A commercially available MLPA Kit (SALSA MLPA Kit P024B; MRC-Holland, 
Amsterdam, the Netherlands) targeting the 9p21 region was used according to the 
manufacturer’s protocol. The P024B kit contains 23 probes of which 9 probes are specific 
for the CDKN2A region, 3 probes for the CDKN2B region and 3 probes for the MTAP 
gene, while 8 probes hybridize to regions flanking these genes. For the experiments we 
used 60-80 ng of genomic DNA and normal control DNA (a DNA mix of 15 healthy 
donors) was always included in the same reaction. The principles of the MLPA technique 
are concisely described by Vorstman et al.14, while detailed methodology can be found in 
the paper by Schouten et al.3  
Briefly, genomic DNA diluted in 5 ul of Tris-EDTA 10mM, was denatured at 95°C for 5 
min, mixed with the probe set and the MLPA buffer, and incubated for 16 hr at 60°C. After 
probe hybridisation, products were ligated for 15 min at 54°C. The ligase enzyme was then 
inactivated by incubation for 5 min at 98°C. The ligation products were subsequently 
amplified by PCR using universal FAM-labelled primers. All these reactions were carried 
out in a PTC-200 Thermal cycler with heated lid (MJ Research, Waltham, Massachusetts). 
The resulting products were separated according to size on an ABI Prism 3730 DNA 
analyzer (Applied Biosystems, Nieuwerkerk aan den IJssel, the Netherlands) by the 
inclusion of GeneScan ROX 500 as internal size standard (Applied Biosystems). Resulting 
fragment analysis chromatograms were sized to standard fragment lengths by GeneMapper 
v3.7 (Applied Biosystems).
Promoter hypermethylation analysis
Since promoter hypermethylation can be involved in gene inactivation, we also evaluated 
the methylation status of the CpG islands, located in the promoter regions of p16 and 
p14ARF, in patients without homozygous loss of (parts of) the CDKN2A gene. Promoter 
methylation status was determined by performing melting curve analysis of bisulfite 
converted and PCR amplified tumour DNA, as described previously.15 Tumour DNA was 
modified with sodium bisulfite by using the EZ Methylation Kit (Zymo Research 
Corporation, Orange, CA). PCR primers were designed to anneal to bisulfite-converted 
DNA as template which amplified a region of the p16 and p14ARF gene promoter CpG 
islands (see Table 2). PCR amplification of bisulfite-treated DNA and subsequent melting 
curve analysis in the presence of SYBRGReen (MyiQ Real-time PCR Detection System; 
Bio-Rad Laboratories BV, Veenendaal, the Netherlands) allowed detection of methylation 
present in the sample DNA, by generating a peak with a higher melting temperature as 
compared to unmethylated DNA. Ratios for methylated versus unmethylated DNA in each 
sample were determined by dividing the total area under the melting temperature curve(s) 
by the area under the methylation specific peak. All samples showing a ratio above 0.3 
were considered to contain methylated tumour DNA.
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Table 2. PCR primer sequences, designed to anneal to bisulfite-converted DNA as template, for 
p16 and p14ARF gene promoter CpG islands. 
Gene Primer sequence (5' - 3') CpGs in Position of Amplicon Relative Amplicon













Data analysis and statistical methods
Analysis of MLPA results was carried out upon the transfer of GeneMapper results to 
Coffalyser software, a data analysis tool which was designed by MRC-Holland for 
normalization of MLPA fragment data files. With this programme, DNA copy number 
ratios of test samples can be computed, by comparison and normalization to a control 
sample (for full description see: http://www.mlpa.com/coffalyser/). Since sample DNA is 
compared against a normal control sample, a ratio of 0.5 would ideally indicate hemizygous 
loss and zero would indicate homozygous loss. However, considering the fact that our 
samples contained a maximum of 30% admixed reactive cells, ratios between 0.4 and 0.7 
were considered as hemizygous loss, while ratios below 0.4 were considered as 
homozygous loss.
For analysis of clinical data and performing survival analyses, SPSS 14.0 (SPSS Inc., 
Chicago, IL, U.S.A.) was used. Disease-specific survival (DSS) was calculated from the 
date of diagnosis until death from lymphoma (including therapy-related death) or last 
follow-up without event. Survival curves were estimated using the method of Kaplan and 
Meier and statistical comparison between curves was done by log-rank testing.
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Summary
Background:  Recently, a consensus proposal was published for a TNM classification 
system for all primary cutaneous lymphomas other than mycosis fungoides and Sézary 
syndrome, meant to document extent of disease in a consistent manner. The applicability 
and the prognostic significance of this system have not been investigated thus far.
Objectives: To test the applicability and prognostic relevance of the proposed TNM 
classification system on a cohort of primary cutaneous B-cell lymphomas (CBCL). 
Patients/ methods: The study group included 71 primary cutaneous marginal zone 
lymphomas (PCMZL), 171 primary cutaneous follicle centre lymphomas (PCFCL) and 58 
primary cutaneous diffuse large B-cell lymphomas, leg type (PCLBCL, LT). Since only 
patients with primary cutaneous lymphoma were included (T1-3, N0M0), only T-rating was 
scored. The results were compared with the scoring as applied by the Dutch Cutaneous 
Lymphoma Group. 
Results: The system was easily applicable to all cases. In PCMZL and PCFCL no 
correlation was found between T-score and survival (5-year disease-specific survival: T1: 
100% and 98%, T2: 94% and 93%, T3: 100% and 88% respectively). In PCLBCL, LT there 
was an obvious, although statistically not significant, association between increasing T-
score and reduced survival (5-year disease-specific survival: T1: 75%, T2: 49%, T3: 0%; p 
= 0.077). Comparing the TNM system with the Dutch Cutaneous Lymphoma Group 
system, there was a discrepancy in the classification of 20 cases.
Conclusions: The new TNM- system is a useful tool to document disease extent in patients 
with CBCL and provides prognostic information in the group of PCLBCL, LT patients.
Keywords: B cell, cutaneous lymphoma, disease extent, prognosis, TNM staging
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Introduction
Recently, representatives of the International Society for Cutaneous Lymphomas and the 
Cutaneous Lymphoma Group of the European Organization for Research and Treatment of 
Cancer (EORTC) published a consensus proposal for a TNM classification system 
applicable to all primary cutaneous lymphomas other than mycosis fungoides and Sézary 
syndrome.1 This proposed TNM system is primarily meant to document extent of disease in 
a consistent manner, thereby facilitating comparison of studies at different institutes. In the 
proposed system the T-classification reflects the extent/ distribution of primary cutaneous 
involvement, the N-classification describes lymph node involvement and the M-
classification is used to describe if extracutaneous non-lymph node disease is present. 
Since, by definition, in all primary cutaneous lymphomas, extracutaneous disease (lymph 
node or visceral) is absent at the time of diagnosis, the N- and M-scores are only used to 
document disease extent at the time of relapse or disease progression. A detailed 
description of the different categories is given in Table 1. 
Studies investigating the applicability of this TNM system have not been performed thus 
far. Moreover, whether this TNM system provides prognostically relevant information for 
the different types of primary cutaneous lymphoma and thus may serve as an additional 
guide in the appropriate management of these lymphomas remains to be elucidated. 
In the present study we applied the proposed TNM system on a  large cohort of 300 primary 
cutaneous B-cell lymphomas (CBCL), recently reclassified according to the new WHO-
EORTC classification.2;3 This classification distinguishes 3 main types of CBCL:  primary 
cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous follicle centre 
lymphoma (PCFCL), both indolent types of CBCL and primary cutaneous diffuse large B-
cell lymphoma, leg type (PCLBCL, LT), which represents a more aggressive type of 
CBCL. Since these groups have been redefined as compared to the formerly used 
classifications4;5, we have summarized the main features of these 3 groups, as found in a 
recent study2, in Table 2. 
The aims of this retrospective cohort analysis were to test the clinical applicability of the 
proposed TNM system and to evaluate its prognostic relevance for the group of CBCL. In 





The study group is a retrospective cohort of 300 CBCL patients reclassified according to 
the criteria of the WHO-EORTC classification.3 In all cases, gender, age at diagnosis, site, 
size and extent of skin lesions (see below), status at last follow-up and duration of follow-
up were recorded as part of a recent study.2 In addition, in approximately 50% of cases 
clinical photographs were available for evaluation.
This group included 71 primary cutaneous marginal zone lymphomas (PCMZL), 171 
primary cutaneous follicle centre lymphomas (PCFCL) and 58 primary cutaneous diffuse 
large B-cell lymphoma, leg type (PCLBCL, LT). 
Table 1. Description of different scres in the TNM classification.
Classification Description
T1 Solitary skin involvement categories:
 T1a a solitary lesion <5 cm diameter
 T1b a solitary lesion >5 cm diameter
T2 Regional skin involvement categories:
Multiple lesions limited to one body region or two contiguous body 
regions
 T2a all disease encompassing in a < 15 cm diameter circular area
 T2b all disease encompassing in a > 15 and < 30 cm diameter 
circular area
 T2c all disease encompassing in a > 30 cm diameter circular area
T
T3 Generalized skin involvement:
 T3a multiple lesions involving 2 non-contiguous body regions
 T3b multiple lesions involving > 3 body regions
N0 No clinical or pathologic lymph node involvement
N1 Involvement of one peripheral lymph node region that drains an area of 
current or prior skin involvement
N2 Involvement of two or more peripheral lymph node regions or involvement 
of any lymph node region that does not drain an area of current or prior 
skin involvement
N
N3 Involvement of central lymph nodes
M0 No evidence of extracutaneous non-lymph node diseaseM
M1 Extracutaneous non-lymph node disease present
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Assessment of disease extent
In all cases extent of skin lesions at the time of diagnosis was scored using the proposed 
TNM system.1 Since only patients with primary cutaneous lymphoma were included (T1-3, 
N0M0), only T-rating was scored (see Table 1 and Figure 1). In case no measurements 
were recorded in the database of the Dutch Cutaneous Lymphoma Group and clinical 
photographs were not available, measurements of skin lesions were obtained from patients 
charts or, in case the patient had undergone radiotherapy, from the files of the radiotherapy 
department. The results were compared with the scoring of the Dutch Cutaneous 
Lymphoma Group, used in our previous study.2 In this Dutch Cutaneous Lymphoma Group 
system, extent of involved skin is defined as solitary when it concerns a single tumour, as 
localized when the lesion consists of multiple skin lesions that can be irradiated within one 
radiation field, and as multifocal for separate lesions in adjacent body regions that can not 
be irradiated within one radiation field or for lesions involving multiple nonadjacent body 
regions. In contrast to the TNM system, no further subdivision is made on the basis of the 
size of the skin lesions or the affected areas.
Figure 1. Body regions as defined in the proposed TNM system for the designation of T-
classification. Left and right extremities are assessed as separate body regions.
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Statistical analysis
Statistical calculations were performed using SPSS 12.0.1 (SPSS Inc, Chicago, IL). 
Disease-specific survival was calculated from the date of diagnosis until death of 
lymphoma or last follow-up without event. Survival curves were estimated using the 
method of Kaplan and Meier and statistical comparison between curves was done by log-
rank testing.
Results 
The median follow-up for the whole group was 56 months (range 2-336 months).
The results of scoring extent of disease by T-score and by the Dutch Cutaneous Lymphoma 
Group  system, as well as the corresponding 5-year disease-specific survival rates, are 
summarized in Table 3. Because of the clear descriptions of the main T-score groups and 
the different subgroups (see Table 1), combined with the strictly defined body regions (see 
Figure 1), this system could be easily applied to all cases. 
The study included 71 PCMZL patients (48 males, 23 females) with a median age of 53 
years (range 23-87). Using the TNM system most patients were classified as T3 (n = 28; 
39%), followed by T2 (n = 25; 35%) and T1 (n = 18; 25%). According to the Dutch 
Cutaneous Lymphoma Group system 36 patients (51%) had multifocal disease, 17 patients 
(24%) had localized disease, while 18 patients (25%) had presented with a solitary lesion. 
Eight cases with multiple separate lesions at adjacent body regions were classified as 
multifocal according to the Dutch Cutaneous Lymphoma Group system, but as T2 using the 
TNM system. Representative examples of the different stages are presented in Figure 2. 
The five-year disease-specific survival for T1, T2 and T3 were 100%, 94% and 100% 
respectively, and 100%, 92% and 100% for solitary, localized and multifocal disease 
according to the Dutch Cutaneous Lymphoma Group  system. These results clearly show 
that extent of disease, either by TNM or Dutch Cutaneous Lymphoma Group system has no 
prognostic significance in this group.
Table 2. Clinical characteristics of the 3 main groups of primary cutaneous B-cell lymphoma.
PCMZL PCFCL PCLBCL, LT
Median age, years 
(range)






solitary or multiple papules, plaques or 
nodules preferentially on the trunk (55%) 
or extremities (67%)
solitary or grouped tumours or plaques 
preferentially on the head (44%) or the trunk 
(54%)
lesions on the leg(s) uncommon (6%)
solitary or multiple nodules and/or 
tumours most often on the leg(s) (88%)
lesions at sites other than the leg(s) 
uncommon 



















Patients with a PCFCL (n = 171; 109 males and 62 females) had a median age of 58 years 
(range 21-89). Using the TNM system, most patients presented with stage T1 (n = 68; 40%) 
or T2 (n = 88; 51%). Only 15 patients (9%) were classified as T3 at the time of diagnosis 
(see Table 3). According to the Dutch Cutaneous Lymphoma Group  system 68 patients 
(40%) had presented with a solitary skin lesion, 76 patients (44%) with localized skin 
lesions and 27 patients (16%) with multifocal skin lesions. Twelve cases with multiple 
separate lesions at adjacent body regions were classified as multifocal according to the 
Dutch Cutaneous Lymphoma Group system, but as T2 using the TNM system. 
Representative examples of the different stages are presented in Figure 3.
The 5-year disease-specific survival for T1, T2 and T3 was 98%, 93% and 88% and 99%, 
95% and 85% for solitary, localized and multifocal according to the Dutch Cutaneous 
Lymphoma Group system respectively. Although there was a tendency toward reduced 
survival with increasing T-score, these differences were not significant (p = 0.560). 
Moreover, no significant differences were found between subgroups within the different T-
categories (T1a vs. T1b; T2a vs. T2b vs. T2c; T3a vs. T3b; see Table 3). 
Patients with PCLBCL, LT (n = 58; 20 males, 38 females) had a median age of 78 years 
(range 42-92). In this group the numbers according to the T-score corresponded entirely 
with the numbers in the extent categories as used by the Dutch Cutaneous Lymphoma 
Group: T1/ solitary 24% (n = 14), T2/ localized 57% (n = 33) and T3/ multifocal 19% (n = 
11) (see Figure 4). Although statistically not significant (p = 0.077) an obvious correlation 
was seen between extent and survival (5-year disease-specific survival of 75%, 49% and 
0% respectively). Moreover, the classification into subgroups within the main T-scores 
provided additional prognostic value. For instance, patients in the T2 group showed a 
decreased survival with increasing size of the affected areas (5-year disease-specific 
survival for involved area of  15 cm, 15-30 cm or > 30 cm is 67%, 48% and 0% 
respectively; see Table 3).
Discussion
This study investigates the applicability and prognostic significance of the newly proposed 
TNM system and describes for the first time how this system is applied to a large group of 
primary cutaneous lymphomas.
Our results show that the TNM system can easily be applied to the three commonest groups 
of CBCL. In both indolent entities, PCMZL and PCFCL, the system does not appear to 
have prognostic significance, but in PCLBCL, LT, the group with an intermediate 
prognosis, increasing T-score seems to be associated with worse survival. In addition, 
subdivision based on the size of the skin lesion or the affected body area, or in case of T3 
classification, the amount of involved body regions, provided additional prognostic 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Consistently, in two recent studies on PCLBCL, LT, patients presenting with a solitary 
tumour had a better prognosis than patients presenting with multiple tumours on one or 
both legs.6;7 However, in a study of 40 PCLBCL, LT by Kodama et al8 no difference in 
survival was found between patients with solitary or multiple tumours. Zinzani et al 
reported a significantly higher overall survival for PCMZL/ PCFCL patients with a single 
skin lesion compared to those with regional/ disseminated disease.7 Since the authors do not 
describe this relation for PCMZL and PCFCL separately, comparison with the results of the 
present study is impossible. 
Comparing the TNM-system with the Dutch Cutaneous Lymphoma Group system, there 
was a discrepancy in the classification of 20 cases (8 PCMZL and 12 PCFCL) with multiple 
separate lesions at two contiguous body regions (see Figure 2B). Since there is no 
anatomical or biological relation between such separate lesions, in the Dutch Cutaneous 
Lymphoma Group such lesions are classified as multifocal or generalized disease, and not 
as regional disease. However, since the T3 category in the TNM system is defined as 
involvement of 2 non-contiguous body regions or 3 or more body regions, such cases are 
not classified as T3, but as T2, which denotes regional skin involvement.  Classification of 
such cases as T2 is of minor clinical importance in PCMZL and PCFCL, since both groups 
represent indolent types of CBCL, which can be treated with non-aggressive therapies, 
irrespective of the extent of skin lesions. However, in other types of lymphoma, classifying 
separate lesions at adjacent body sites as T2 might have important therapeutic 
consequences.
In conclusion, our results show that the proposed TNM system provides the clinician with a 
useful tool to document the disease extent in patients with CBCL in a consistent manner. In 
cases of PCLBCL, LT it also provides prognostic information. The applicability of the 
definitions for T2c and T3a/b should be evaluated in cohorts of other types of primary 
cutaneous lymphomas, because this might have undesirable therapeutic consequences.
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Figure 2. Examples of different T-scores in primary cutaneous marginal zone lymphoma. A: 
T2a; Dutch Cutaneous Lymphoma Group: localized, B: T2c; Dutch Cutaneous Lymphoma Group: 
multifocal.
Figure 3. Examples of different T-scores in primary cutaneous follicle centre lymphoma.
A: T1b; Dutch Cutaneous Lymphoma Group: solitary, B: T2b; Dutch Cutaneous Lymphoma Group : 





Figure 4. Examples of different T-scores in primary cutaneous diffuse large B-cell lymphoma, 
leg type. A: T1a; Dutch Cutaneous Lymphoma Group : solitary, B: T2a; Dutch Cutaneous 
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Summary
Recently, discussions have started whether or not bone marrow biopsies should be 
performed routinely in patients with skin lesions that show histologic features consistent 
with an indolent B-cell lymphoma (marginal zone lymphoma (MZL) or follicle centre 
lymphoma (FCL). As no studies have addressed this question for this group of lymphomas, 
we evaluated the results of bone marrow biopsy examination in 275 patients with histologic 
features consistent with MZL (n = 82) or FCL (n = 193) first presenting in the skin. In the 
MZL group, two of 82 patients (2%) showed bone marrow involvement and in one of these 
patients this was the only extracutaneous localization. In the group of FCL, 22 of 193 
patients (11%) had bone marrow involvement. In nine of these this was the only 
extracutaneous localization. FCL patients with skin lesions and a positive bone marrow had 
a significantly worse prognosis as compared to patients with only skin lesions (5-year 
disease-specific survival 63% versus 95%; p = 0.001).
These results indicate that bone marrow investigation is an essential part in staging patients 
with a FCL first presenting in the skin. Bone marrow examination appears to have limited 
value in patients with MZL presenting in the skin.
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Introduction
Primary cutaneous lymphomas (PCL) are defined as a group of non-Hodgkin lymphomas 
of either T-cell or B-cell origin, that present in the skin without evidence of extracutaneous 
disease at the time of diagnosis. Distinction between PCL and systemic lymphomas 
involving the skin secondarily is important since they often have a completely different 
clinical behaviour and prognosis, and may therefore require different types of treatment.1
A diagnosis of PCL can only be made after adequate staging investigations have been 
conducted. Adequate staging procedures include, besides a detailed history and physical 
examination, routine laboratory tests (complete and differential blood cell count and serum 
biochemistry), computed tomography (CT) scan of neck, chest and abdomen and a bone 
marrow biopsy. At recent consensus meetings of the European Organization for Research 
and Treatment of Cancer (EORTC) and the International Society of Cutaneous Lymphoma 
(ISCL), aimed to develop staging systems and guidelines for diagnosis and treatment of 
PCL other than mycosis fungoïdes (MF) and Sézary syndrome (SS), the necessity to 
perform a bone marrow biopsy in indolent PCL was questioned. In the subsequent 
consensus paper, it was suggested that bone marrow examination was recommended, but 
not required in indolent PCL, including primary cutaneous anaplastic large cell lymphoma, 
primary cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous follicle 
centre lymphoma (PCFCL), unless indicated by other staging assessments.2 Regarding the 
two types of indolent cutaneous B-cell lymphoma (CBCL), this is in accordance with the 
National Comprehensive Cancer Network (NCCN) clinical practice guidelines [v.1.2007: 
available from: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf. Accessed 31 
July; 2007]. In these guidelines bone marrow biopsies are not part of the essential workup 
of follicular lymphoma and marginal zone lymphoma and are only advised in selected 
cases. However, in most other guidelines, including those of the Dutch-Belgian Hemato-
Oncology Group (HOVON) [available from: 
http://www.hovon.nl/hovon/stream.asp?hovnhl.pdf. Accessed 31 July; 2007], unilateral 
trephine bone marrow biopsies are part of routine work-up in all patients with (a suspicion 
of) non-Hodgkin lymphoma.3;4
The recommendation that a bone marrow biopsy is not required in indolent types of CBCL 
(PCMZL and PCFCL) is confusing, since studies describing these PCMZL and PCFCL as 
indolent lymphomas required negative staging procedures, including a negative bone 
marrow biopsy.1 Henceforth, this recommendation means that in patients who present with 
skin lesions that are clinically and histologically highly suggestive or consistent with a 
diagnosis of PCMZL or PCFCL a bone marrow is not required, if other staging procedures 
are negative. In case of marginal zone lymphoma the consequences of not performing a 
bone marrow biopsy are expected to be limited. In case staging (including a bone marrow 
biopsy) is negative, it concerns a PCL, which, - according to the WHO-EORTC 
classification for cutaneous lymphomas -, is classified as PCMZL. If, however, a bone 
marrow biopsy and/or other staging procedures are positive, it does not concern a PCL, and 
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the WHO-EORTC classification should not be applied. Such cases should be classified 
according to the WHO classification as an extranodal marginal zone lymphoma with skin 
localizations. In both instances it concerns an indolent type of B-cell non-Hodgkin 
lymphoma, and the therapeutic consequences will be minimal. In case of PCFCL the 
situation is more complex. PCFCL are defined as tumors of neoplastic follicle center cells, 
usually a mixture of centrocytes and variable numbers of centroblasts, which may show a 
follicular (5%), follicular and diffuse (30%) or diffuse growth pattern (65%).5 These 
PCFCL are preferably treated with radiotherapy and have an excellent prognosis with a 5-
year-survival of 95%, irrespective of the growth pattern (follicular and/or diffuse) or the 
number of blast cells.1 However, if in a patient with clinicopathologic features suggesting a 
PCFCL, a bone marrow biopsy and/or other staging procedure prove to be positive, a 
diagnosis of PCFCL can not be made. Such cases concern a secondary cutaneous 
lymphoma and should be classified according to the WHO classification as either follicular 
lymphoma or, in most cases, as a diffuse large B-cell lymphoma, which will have major 
therapeutic consequences. One would therefore assume that not performing a bone marrow 
biopsy in such cases may result in inappropriate treatment. 
Studies on the frequency of extracutaneous manifestations and in particular a positive bone 
marrow biopsy in patients presenting with skin lesions otherwise consistent with a PCMZL 
or PCFCL have never been performed. In the present study we therefore evaluated 
retrospectively staging results of a large group of patients presenting with skin lesions that 
showed histological features consistent with a diagnosis of marginal zone lymphomas 
(MZL) or follicle centre lymphomas (FCL). The aim was to evaluate the frequency of bone 
marrow involvement in these patients in order to find out whether our current policy to 
perform a bone marrow biopsy in all patients with a histological diagnosis of cutaneous 
MZL or FCL should be maintained or that it should only be performed in selected cases as 
suggested recently.2
Patients and Methods
All patients who presented with skin lesions showing histologic and immunophenotypical 
features consistent with a diagnosis of MZL (n = 107) or FCL (n = 250) between 1985 and 
2006 were retrieved from the database of the Dutch Cutaneous Lymphoma Group. The 
term FCL is herein used for tumors of neoplastic follicle centre cells with either a follicular, 
a follicular and diffuse or a diffuse growth pattern, which should be classified as PCFCL, in 
case staging procedures were negative. All cases had been reviewed by a panel of 
hematopathologists and dermato(patho)logists and classified by consensus prior to entry in 
the database. For each patient in this registry follow-up is collected yearly. Patients with a 
history of a prior systemic B-cell lymphoma (n = 16; 2 MZL and 14 FCL) and patients in 
whom a bone marrow biopsy was not performed (n = 66; 23 MZL and 43 FCL) were 
excluded from the study. The final study group consisted of 82 MZL and 193 FCL (Table 
1). Median follow-up for the whole group was 43 months (range 1 – 443 months). Staging 
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procedures had included physical examination, complete and differential blood cell counts 
and serum biochemistry, CT-scan of neck, chest and abdomen and a bone marrow biopsy. 
The results of the staging investigations were extracted from the patient’s files. 
Statistical calculations were performed using SPSS 14.0 (SPSS Inc, Chicago, IL). Overall 
survival (OS) was calculated from the date of diagnosis until the patient’s death or date of 
last follow-up. Disease-specific survival (DSS) was calculated from the date of diagnosis 
until death from lymphoma (including therapy-related death) or censoring. Patients who 
were alive at last follow-up or patients who died of other causes were considered censored. 
Survival curves were estimated using the method of Kaplan and Meier and statistical 
comparison between curves was done by log-rank testing.
Table 1. Selection of cases and results of bone marrow biopsy and disease-specific survival 
(DSS) in marginal zone lymphomas and follicle center lymphomas first presenting in the skin.
Histology Marginal zone lymphoma Follicle centre lymphoma
Total number present in database 
DCLG (*)
107 250
History of non-cutaneous lymphoma 2 14
Bone marrow biopsy not performed
(5-year DSS)
23 (100%) 43 (86%)
Final study group (5-year DSS) 82 (92%) 193 (86%)
Male: female 52:30 118:75
Median age (range) 57 (23-90) 59 (21-90)
Median duration of follow-up, 
months (range)
31 (1-334) 51 (1-443)
Staging negative (5-yr DSS) 76 (98%) 157 (95%)
Staging positive (5-yr DSS) 6 (50%) 36 (51%)
Bone marrow involvement 
(5-yr DSS)
2 (50%) 22 (51%)
Only bone marrow involvement
(5-yr DSS)




In the group of 82 MZL patients, 76 patients showed no signs of extracutaneous 
involvement during staging investigations and were diagnosed as PCMZL (see Table 1).1 In 
six cases (7%) extracutaneous localizations were found, including five patients with 
enlarged lymph nodes on the CT-scan. Bone marrow involvement was found in two of 
these six patients, in one of them as part of widespread disease with involvement of central 
lymph nodes and peripheral blood as well, and in the other patient as the only evidence of 
extracutaneous disease. The first patient was treated with chemotherapy, but died from 
secondary acute myeloid leukaemia three years after diagnosis. The second patient is in 
complete remission for over five years following an autologous bone marrow 
transplantation and radiotherapy for a skin relapse during follow-up. Patients with and 
without extracutaneous involvement had a 5-year OS of 33% and 91%, respectively and a 
5-year DSS of 50% and 98% respectively (Table 1). 
Figure 1: Disease-specific survival of follicle center lymphomas first presenting in the skin; 
cases with positive staging (n = 36) versus cases with negative staging (i.e. true PCFCL; n = 
157).
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negative staging (n = 157)




Of 193 FCL patients with complete staging work-up 157 patients showed no evidence of 
extracutaneous disease and were classified as PCFCL.1 Extracutaneous disease was 
detected at the time of diagnosis in 36 cases (19%). Nine of 36 cases showed the 
characteristics of a follicular lymphoma, while the other 28 cases lacked a follicular 
component and were classified as diffuse large B-cell lymphoma.  Taken together, in 22 of 
these 36 cases the bone marrow biopsy was positive or contained lymphoid aggregates 
highly suspect for lymphoma involvement (Table 1). In 13 patients, bone marrow 
involvement was accompanied by more extensive involvement of other organs or lymph 
nodes as assessed by CT-scans and/or lymph node histology. In the remaining nine cases 
the bone marrow was the only extracutaneous localization. The 14 patients with 
extracutaneous disease, but no bone marrow involvement showed nodal disease as assessed 
by CT-scan and/or lymph node biopsy (n = 13), while one patient showed bone 
involvement.
The 5-year OS for the 36 patients with and the 157 patients without extracutaneous 
involvement was 42% and 84%, respectively, whereas the 5-year DSS was 52% and 95% 
respectively (p < 0.001; Figure 1). Patients with bone marrow involvement with or without 
extracutaneous localizations at other sites had a 5-year OS of 30% and 44% and a 5-year 
DSS of 30% and 63%, respectively (Table 1).
Figure 2: Disease-specific survival of follicle center lymphomas first presenting in the skin; 























Recently, discussions have started whether or not bone marrow biopsies should be routinely 
performed in patients with a MZL or FCL first presenting in the skin.2 Since there are, to 
the best of our knowledge, no studies that have addressed this question for this particular 
group of lymphomas, we evaluated the results of bone marrow biopsy examinations in 275 
patients with a MZL or FCL first presenting in the skin. Considering the whole group of 
275 patients, 24 patients (9%) had bone marrow involvement at initial diagnosis, while in 
10 patients (4%) this was the only evidence of extracutaneous disease.
In the group of MZL, bone marrow was involved in only two of 82 (2%) patients, and in 
one of these two patients it was the only evidence of extracutaneous disease. Thus, if bone 
marrow biopsies would not have been performed in this group, only one of 82 cases would 
have been misdiagnosed as PCMZL. 
Recent studies on large cohorts of nongastric extranodal marginal zone B-cell lymphoma of 
mucosa-associated lymphoid tissue (MALT lymphoma), report bone marrow involvement 
at initial diagnosis in 14% to 28% of patients.6-8 Cutaneous MZL included in these studies 
showed bone marrow involvement in zero of seven7 and two of 22 (9%)8 cases, 
respectively. Since MALT lymphomas present with disseminated disease in a considerable 
proportion of cases, these studies emphasize the need of extensive staging procedures, 
including a bone marrow biopsy. In addition, in these studies bone marrow involvement 
was associated with an inferior prognosis. In contrast, a recent Austrian study found bone
marrow involvement in only three of 140 (2%) MALT lymphomas, including one of 79 
(1%) nongastric MALT lymphomas, thus arguing against the necessity of a routine bone 
marrow biopsy. 9The different frequencies of bone marrow involvement in these studies are 
as yet unexplained. 
The results of the present study and data from the literature indicate that bone marrow 
involvement is uncommon in MZL first presenting in the skin, and that it is rarely the only 
manifestation of extracutaneous disease. Moreover, treatment of MZL with skin lesions and 
isolated bone marrow involvement will not be different from that of MZL presenting with 
only skin lesions (PCMZL). In both cases, radiotherapy will be the primary option, 
although the (known) presence of bone marrow involvement will ask for a closer follow-up 
of such a patient compared to the patient with only skin involvement.  It is also interesting 
to note that the 23 patients with cutaneous MZL in whom no bone marrow biopsy was 
performed, and who were excluded from the present study, had a 5-yr DSS of 100% (see 
Table 1). Thus, from a clinical point of view, there does not seem to be a good reason to
consider a bone marrow biopsy mandatory in these patients. However, if bone marrow 
biopsies are no longer performed, a definite diagnosis of PCMZL can no longer be made 
with certainty. Given the major pathogenetic differences in terms of translocations and 
antigenic stimuli involved in the development of MALT lymphomas at different sites10-12, 
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not performing a bone marrow biopsy may obscure distinction between primary and 
secondary cutaneous cases and hamper elucidation of the pathogenesis of genuine PCMZL. 
In the group of FCL first presenting in the skin, bone marrow was involved in 22 of 193 
cases (11%), whereas bone marrow involvement was the only evidence of extracutaneous 
disease in nine of them. Thus, if bone marrow biopsies had not been performed in this 
group, nine cases would have been incorrectly classified as PCFCL. The finding of bone 
marrow involvement in these nine patients appears clinically relevant, since they had a 
significantly worse survival as compared to the 157 PCFCL patients (5-year OS 44% versus 
84%; p = 0.001; 5-year DSS 63% versus 95%; p = 0.001; Figure 2). In addition, although 
the clinical presentation (site and extent of skin lesions) in these nine patients did not differ 
from patients with a PCFCL, the presence of bone marrow involvement may also have 
therapeutic consequences.
In three of nine cases the skin infiltrates showed a partial follicular growth pattern and were 
classified as follicular lymphoma with skin and bone marrow involvement. In the other six 
cases the skin biopsies showed a diffuse population of large cleaved cells without a 
follicular component and were classified as diffuse large B-cell lymphoma according to the 
WHO classification. Taken together, these data indicate that a bone marrow biopsy is 
mandatory in patients with a FCL first presenting in the skin. 
Due to the fact that these patients were collected during a 20-year period, all data were 
retrieved from a database or patient’s files, and some of these could not be reviewed. The 
quality of CT scans has very much improved, and PET scans have recently contributed to 
the upgrading of staging procedures. As far as bone marrow biopsies are concerned, much 
has changed during the last decade. The Cheson guidelines3 request a well-defined quality, 
regarding length of the specimen (>2 cm) with sufficient marrow fields, and in the case of 
doubtful infiltration additional immunohistochemistry, which obviously was not available 
in the early years of this study. Although some false-positive marrows might have been 
present, one would rather expect false-negative bone marrows. We therefore believe that 
there are two reasons why the percentage of positive bone marrow biopsies might be even 
higher than found in our study. First, in the absence of a histologic review of the bone 
marrow biopsies,  it can not be excluded that some designated negative, were in fact of 
insufficient quality to allow a definite conclusion. Exclusion of such ‘false-negative’ bone 
marrow biopsies would result in a higher percentage of positive bone marrow examinations. 
Second, one of the main goals of the Dutch Cutaneous Lymphoma Group is to assist 
referring dermatologists and pathologists in making a correct diagnosis of patients with 
(suspicion of) a cutaneous lymphoma.  Although the database contains both primary and 
secondary cutaneous lymphomas, patients presenting with skin lesions and extensive 
extracutaneous disease, and who were primarily referred to a haematologist, may not have 
been included in the Dutch Cutaneous Lymphoma Group database. If such patients would 
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have been included, the percentage of positive bone marrow biopsies would definitely have 
been higher. However, we believe that this will apply to only a few patients as compared to 
the large number of cases included in this study, and therefore will not significantly 
influence our conclusions.  
In conclusion, the results of our study indicate that bone marrow investigation is an 
essential part of staging procedures in patients with a FCL first presenting in the skin. From 
a clinical point of view, bone marrow examination appears to have limited value in patients 
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Objective: To evaluate the results of radiotherapy in patients with primary cutaneous B-
cell lymphoma (CBCL) classified according to the criteria of the WHO-EORTC 
classification.
Design: A multicenter, 20-year, retrospective, cohort analysis.
Setting: Eight dermatology departments collaborating in the Dutch Cutaneous Lymphoma 
Group.
Patients: From 1985 until 2005 153 CBCL patients were initially treated with radiotherapy
with curative intent. These cases were classified according to the WHO-EORTC 
classification and consisted of 25 primary cutaneous marginal zone lymphoma (PCMZL), 
101 primary cutaneous follicle centre lymphoma (PCFCL) and 27 primary cutaneous large 
B-cell lymphoma, leg type (PCLBCL, LT).
Interventions: Local radiotherapy with a median dose of 40 Gy (range 20-46 Gy) applied 
to all visible skin lesions.
Main Outcome Measures: Complete remission rate, relapse rate, 5-year relapse-free 
survival, 5-year overall survival and 5-year disease-specific survival (DSS).
Results: Complete remission was reached in 151 of 153 (99%) patients. Relapse rates for 
PCMZL, PCFCL and PCLBCL, LT were 60%, 29% and 64% and the 5-year DSS was 
95%, 97% and 59% respectively. PCFCL presenting on the leg(s) had a higher relapse rate 
(63%) and a much lower 5-year DSS (44%) as compared to PCFCL presenting at other sites 
(relapse rate: 25% and 5-year DSS: 99%). 
Conclusions: Radiotherapy is a suitable treatment for a large group of CBCL patients. 
However, patients with PCFCL presenting with lesions on the leg(s) and patients with 
PCLBCL, LT display a more unfavourable clinical course and should therefore be treated 
with more aggressive treatment modalities.
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Introduction
The term primary cutaneous B-cell lymphomas (CBCL) refers to a heterogeneous group of 
B-cell non-Hodgkin lymphomas, that present in the skin without evidence of 
extracutaneous disease at the time of diagnosis. In the past years there has been much 
debate regarding the terminology and classification of these lymphomas. Recently, 
representatives of the European Organization for Research and Treatment of Cancer 
(EORTC) classification and the World Health Organisation (WHO) classification have 
reached consensus regarding a new classification for primary cutaneous lymphomas. In this 
WHO-EORTC classification three main types of CBCL are recognized: primary cutaneous 
marginal zone lymphoma (PCMZL) and primary cutaneous follicle centre lymphoma 
(PCFCL), both indolent types of CBCL with a 5-year disease-specific survival over 95%,  
and primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT), which 
represents a more aggressive type of CBCL with a 5-year-disease-specific survival of 
approximately 50%.1
Previous studies have shown that radiotherapy (RT) is a suitable treatment in both types of 
indolent CBCL, and perhaps also in PCLBCL, LT presenting with  solitary or localized 
skin lesions.2-6 However, data from the literature regarding efficacy and relapse rate show a 
wide variation.2;3;5;7-10 Moreover, these studies are all based on cases classified according to 
the EORTC11 or WHO12 classifications. In a recent study we showed that approximately 
5% and 36% of cases formerly classified according to the EORTC and WHO classifications 
respectively, were assigned to another prognostic category, when the WHO-EORTC 
classification was used.13 These observations prompted us to evaluate the results of RT as 
initial treatment in CBCL reclassified according to the criteria of the new WHO-EORTC 
classification. 
The purpose of this retrospective study was to define complete remission (CR) rates, 
relapse rates, relapse-free survival (RFS), 5-year overall survival (OS) and 5-year disease-
specific survival (DSS) following RT for these newly defined groups of CBCL, and to 
establish for which patients RT is a safe and effective mode of treatment. 
Patients and Methods
Selection of patients
Between 1985 and 2005 320 patients with CBCL were included in the registry of the Dutch 
Cutaneous Lymphoma Working Group. Follow-up data had been collected each year from 
patients' medical charts or referring physicians. In a recent study clinical data and 
histological sections of 300 CBCL were reviewed and reclassified according to the criteria 
of the new WHO-EORTC classification.13 This group included 174 patients, who had 
received RT as initial treatment. Patients in which RT was administered in palliative 
dosages with no intention to be curative were excluded (n = 7), as were patients with a short 
follow-up of less than 12 months (n = 14). However, patients that died within 12 months 
after diagnosis due to their lymphoma were not excluded from the study. The final study 
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group consisted of 153 CBCL. According to the WHO-EORTC classification this group 
included 25 PCMZL, 101 PCFCL and 27 PCLBCL, LT (see Figure 1). 
For all patients the following data were recorded: age at diagnosis, gender, involved skin 
site, extent of involved skin, result of initial therapy, occurrence and site of relapse, relapse 
treatment, result of relapse treatment, duration of follow-up and status at last follow-up. 
Extent of involved skin was defined as solitary when it concerned a single tumour, 
localized when the lesion consisted of multiple plaques and/or tumours that could be 
irradiated within one radiation field and multifocal if multiple nonadjacent body sites were 
involved or when the lesion(s) could not be irradiated within one radiation field. 
Treatment
Most patients had been treated with electron beam irradiation (4 to 10 MeV), while nine 
patients received 6 to 10 MV photon beams. The radiation dose varied between 20 and 46 
Gy, with a median dose of 40 Gy. In all patients, a margin of at least 2 cm of healthy skin 
was included in the radiation field. In PCFCL localized on the trunk, which often present 
with tumors surrounded by annular erythemas, the erythematous areas were included in the 
radiation field because they represent early manifestations of the neoplastic process.14-16
Treatment response was evaluated 4-6 weeks after the end of radiotherapy by clinical 
examination and classified as CR, partial remission (PR), no response (NR) and progressive 
disease (PD); CR was defined as the disappearance of all visible skin lesions, PR was 
defined as a 50% or more remission of clinical lesions, NR as less than 50% remission and 
PD as development of new skin lesions during treatment. Outcome measures for results of 
RT were complete remission (CR) rate, relapse rate, 5-year relapse-free survival (5-yr 
RFS), 5-year overall survival (5-yr OS) and 5-year disease-specific survival (5-yr DSS). 
Statistical analysis
Overall survival was calculated from the date of diagnosis until the patient’s death or last 
follow-up without event. Disease-specific survival was calculated from the date of 
diagnosis until death of lymphoma or last follow-up without event. Relapse-free survival 
was calculated from the date complete remission was reached until first relapse or last 
follow-up without event. Survival curves were estimated using the method of Kaplan and 
Meier and statistical comparison between curves was done by log-rank testing. The 2 test 
was used to analyze differences between subgroups. All statistical analyses were done with 
Statistical Product and Services Solutions software, version 12.0.1 (SPSS Inc, Chicago, Ill). 
Results 
The total group consisted of 87 men and 66 women, with a median age of 63 years (range 
23-92 years). Median follow-up for the whole group was 62 months (range 3-336 months). 
The clinical characteristics, results of RT and follow-up data of the total group of CBCL are 
presented in Table 1. Clinical characteristics, treatment results and follow-up data of the 
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three subgroups of CBCL are also summarized in Table 1 and will be described in more 
detail below.
Primary cutaneous marginal zone B-cell lymphoma 
The group of PCMZL consisted of 18 men and seven women, with a median age of 49 
years (range 23-79 years). Nine patients had a solitary lesion, five patients had localized 
skin lesions, while 11 patients presented with multifocal disease. Most patients presented 
with lesions on the trunk or arms (see Table 1). 
RT resulted in a complete remission in all 25 patients. Fifteen patients (60%) experienced a 
relapse after a median relapse-free interval of 16 months (range 3-144 months). Twelve of 
these patients showed relapses confined to the skin, one patient had a cutaneous and an 
extracutaneous relapse and two patients experienced an extracutaneous relapse without 
concurrent skin lesions. Cutaneous relapses always occurred at unirradiated sites. Patients 
with a PCMZL had an excellent prognosis with a 5-yr OS and DSS of 90% and 95%, 
respectively (see Figure 2).
Primary cutaneous follicle center lymphoma 
The PCFCL group consisted of 61 men and 40 women, with a median age of 58 years 
(range 27-85 years). Most patients (93/101; 92%) presented with solitary lesions (n = 48) or 
localized skin lesions (n = 45). Only eight of 101 patients had multifocal disease at the time 
of presentation. The large majority presented with the typical lesions on the head (n = 41) 
or trunk (n = 55). Eight patients had lesions on one (n = 7) or both (n = 1) leg(s). Six of 
these eight patients were previously classified as PCLBCL, leg following the EORTC 
classification. RT resulted in a complete remission in all 101 patients. A relapse was noted 
in 29 of 101 cases, two to 62 months (median 12 months) after initial treatment. In 21 
patients the relapse was confined to the skin, three patients had a relapse in the skin and an 
extracutaneous localization, while 5 patients had a relapse at an extracutaneous site without 
concurrent skin lesions. All cutaneous relapses occurred outside the irradiated area. Skin 
relapses were generally treated with an additional course of RT, which resulted in another 
CR in all cases. Ultimately, 10 of 101 patients developed extracutaneous disease and four
of 101 patients died of lymphoma. The five-year OS and 5-yr DSS survival was 90% and 
97% respectively (see Figure 2).
Comparison between PCFCL with (solitary or localized) lesions confined to the head (n = 
38) or trunk (n = 48) showed no difference in relapse rate (26% vs. 21%) or 5-yr DSS (95% 
vs. 98%). However, PCFCL presenting with lesions on the leg(s) (n = 8) had a higher 
relapse rate (63% versus 25%; p = 0.028), developed more often extracutaneous disease 
(38% versus 8%; p = 0.006), and had a considerably lower 5-yr DSS (44% versus 99%; p < 
0.001), compared to the patients without lesions on the leg(s). 
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Our study group contains only five PCFCL presenting with multifocal skin lesions without 
involvement of the leg. Three of these five patients had a relapse in the skin; one of these 
three patients eventually developed intracerebral lesions and died of the lymphoma 26
months after the initial diagnosis. 
Comparison between PCFCL with a follicular or follicular and diffuse growth pattern (32 
cases; classified as cutaneous follicle center lymphoma in the WHO classification) and 
PCFCL with a diffuse growth pattern (69 cases; classified as diffuse large B-cell lymphoma 
(DLBCL) in the WHO classification) showed no significant difference in relapse rate 
(13/32; 41% vs. 16/69; 23% resp; p = 0.072) and no difference in DSS (100% vs. 95% resp; 
p = 0.712) between the 2 groups. This illustrates the fact that the growth pattern of the 
malignant infiltrate has no prognostic significance and does not justify more aggressive 
treatment.
Primary cutaneous large B-cell lymphoma, leg type 
The PCLBCL, LT group contained eight men and 19 women. The age at diagnosis in this 
group (median 78 years, range 50-92 years) was considerably higher as compared to the 
other two groups. Twenty-five of 27 patients presented with skin lesions on the leg(s), 
while one patient presented with a solitary tumour on the scalp and another patient had 
lesions localized to the left forearm. These two patients were formerly classified as primary 
cutaneous follicle center cell lymphoma (PCFCCL) in the EORTC classification. 
According to the WHO classification all 27 patients would have been classified as DLBCL. 
Twelve patients had a solitary lesion at initial diagnosis and 15 patients presented with 
localized disease. This group did not contain patients presenting with multifocal skin 
lesions.
RT resulted in a complete remission in 25 of 27 patients (93%). In two patients, including 
the patient presenting with a solitary tumor on the scalp, new skin lesions developed outside 
the irradiated areas during initial radiotherapy, and both patients died of lymphoma three 
and nine months after diagnosis. The patient previously classified as PCFCCL (EORTC 
classification) and presenting with skin lesions on the left forearm reached a sustained 
complete remission now for more than five years.
Of the 25 patients that did reach a complete remission, seven patients relapsed only in the 
skin, four in the skin as well as in an extracutaneous site, while five patients showed only 
extracutaneous relapses. Two of the 11 skin relapses were located within the irradiated area, 
although the cumulative dose in these patients (36 and 40 Gy) was comparable to that of the 
other patients.
Ultimately, 10 patients showed extracutaneous dissemination and 11 patients died due to 
lymphoma. For the total group of PCLBCL, LT the 5-yr OS was 40% and the 5-yr DSS 
was 59% (see Figure 2). Comparison between patients presenting with a solitary lesion and 
patients presenting with multiple localized skin lesions did not show significant differences 
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In the present study we evaluated the results of RT in 153 patients with a CBCL, 
reclassified according to the criteria of the WHO-EORTC classification. 
PCFCL formed the largest group (101 of 153 patients; 66%). In the WHO-EORTC 
classification these PCFCL are defined as a tumor of neoplastic follicle center cells, with a 
predominance of (large) centrocytes and variable numbers of centroblasts, which may have 
a follicular, a follicular and diffuse or a diffuse growth pattern, and which generally present 
on the head or trunk, and uncommonly on the legs.1 In the EORTC classification these rare 
cases presenting on the legs were included in the category PCLBCL, leg.11  The results of 
our study showed CR following initial RT in all 101 cases. The 5-yr RFS was 70% (see 
Figure 3). Twenty-one patients showed one or multiple relapses confined to the skin, while 
eight patients relapsed at extracutaneous sites with or without concurrent skin lesions. No 
infield recurrences were observed. In most patients skin relapses were successfully treated 
again with RT. The 5-yr DSS and OS of the total group were 97% and 90%, respectively. 
These observations are consistent with the results of most previous studies in patients with 
PCFCCL as defined by the criteria of the EORTC classification,3;5;7;10 but differ 
considerably from the results reported by Piccino and coworkers.8;9 These authors 
performed a retrospective study of 102 PCFCCL and found a relapse rate of 75% and a 5-yr 
RFS of only 23%. Moreover, infield relapses were noted in 18 of 102 cases. These 
differences might be explained by the use of orthovoltage techniques and the narrow 
margins (0.5-1.0 cm.) of clinically uninvolved skin included in the irradiation field, as 
previously postulated.7 The reported survival data and the low proportion of patients 
developing extracutaneous disease however, are comparable in all these studies, which 
illustrates the favorable biologic behavior of this lymphoma.
Subgroup analysis showed that patients presenting with skin lesions on the leg more often 
relapsed, more often developed extracutaneous disease, and had a much more unfavorable 
prognosis than patients presenting with skin lesions on the head or trunk. These 
observations confirm the results of recent studies and suggest that presentation on the leg is 
an unfavorable risk factor in PCFCL.13;17 It also suggests that such cases should not be 
treated routinely with radiotherapy. 
Patients presenting with multifocal skin lesions represent another subgroup subjected to 
much debate.2;3;9;18 In a previous study of our group it was found that PCFCL presenting 
with multifocal skin lesions have the same clinical behavior and prognosis as PCFCL 
presenting with solitary or localized skin lesions.2 RT of all visible skin lesions proved 
equally effective as multi-agent chemotherapy. In fact, (skin) relapses were observed in 
three of nine patients treated with multi-agent chemotherapy and not in any of the five
patients treated with RT. The present study group contained only five PCFCL presenting 
with multifocal skin lesions, but not located on the leg. Three of these five patients relapsed 
in the skin, and one of them died of CNS involvement. 
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Recent analysis of 13 PCFCL with multifocal skin lesions (excluding localization on the 
leg) treated with multi-agent chemotherapy showed (skin) relapses in 4/13 patients, while 
one of them developed extracutaneous disease during follow-up (unpublished data). Taken 
together, these small series do not allow firm conclusions to be drawn. Prospective 
collaborative studies on larger numbers of patients are required to evaluate if PCFCL 
presenting with multiple skin lesions can indeed be treated safely and effectively with RT. 
Figure 2. Disease-specific survival after radiotherapy according to diagnostic category.
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PCLBCL, LT are defined as tumors with a predominance or confluent sheets of 
centroblasts and immunoblasts, characteristically presenting with skin lesions on the 
(lower) legs. Cases with a similar morphology and phenotype (strong Bcl-2 and MUM-1 
expression) arising at sites other than the leg are included in this group. In the EORTC 
classification such cases were included in the group of PCFCCL. In recent studies it was 
found that cases presenting on the leg and cases presenting at other sites have a similar 
clinical behavior and prognosis, indicating that reclassification of such cases as PCLBCL, 
LT is an improvement.13;17 In the present study 25 of 27 patients presented with skin lesion 
on the legs, while two patients presented with skin lesions at other sites. In general, patients
with PCLBCL, LT should be treated as other systemic DLBCL, for instance, with a 
regiment of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in 
combination with Rituximab (anti-CD20 antibody). However, in a previous European 
multicenter study including 48 PCLBCL, leg, patients presenting with a solitary  tumor on 
one leg had a significantly better prognosis than patients presenting with multiple tumors on 
one or both legs.13;17;19 It was therefore suggested that patients with a solitary tumor could 
be treated with radiotherapy, while all other patients in this group should be treated with 
systemic chemotherapy. The results of the present study do not support this suggestion. No 
difference in relapse rate and OS and DSS were observed between patients with a solitary 
lesion and patients presenting with multiple localized lesions.
Moreover, two patients developed new skin lesions outside the irradiated areas still during 
initial treatment, and 16 of the other 25 patients showed relapses after initial therapy. In 
addition, this was the only group in which skin relapses developed within a previously 
irradiated area (2 patients). Only 9 of 27 patients showed a sustained CR after initial RT. 
Taken together, these results indicate that RT should not be used as first line treatment in 
these PCLBCL, LT, irrespective of the number of skin lesions. These patients should be 
routinely treated as other DLBCL following current protocols. Only in patients, who do not 
tolerate systemic chemotherapy because of a poor clinical condition or patients who refuse 
this type of treatment, RT may be considered as an alternative option.
As described recently20, RT is also a highly effective treatment in PCMZL, either 
presenting with a solitary or few scattered lesions. However, the relapse rate in PCMZL 
proved much higher than in PCFCL (5-year RFS 36% versus 70%, respectively, see Figure 
3). In patients presenting with many scattered skin lesions, RT is no longer first choice of 
treatment. In such patients beneficial effects have been reported of chlorambucil20 or 
intralesional treatment with interferon alpha or rituximab.21-23 In patients developing 
chronically relapsing disease, treatment is aimed at palliation and no longer at cure, and 
therefore the benefits of treatment should be weighed carefully against their potential side 
effects. In such patient, an expectant policy should be considered. The results of a recent 
pilot study suggest that low dose RT with 2 x 2 Gy is a useful alternative for such patients 
experiencing multiple skin relapses. (Neelis K.J. et al, manuscript in preparation)
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Figure 1.Clinical examples of the studied disease entities. 
A. Primary cutaneous marginal zone lymphoma. B. Primary cutaneous follicle centre lymphoma. 






Figure 3. Relapse-free survival after radiotherapy according to diagnostic category.
In conclusion, the results of our study indicate that RT is a safe and effective treatment in 
many patients with CBCL. In PCFCL and PCMZL, RT is the first line of treatment, not 
only in patients presenting with solitary or localized skin lesions, but probably also in 
patients presenting with few scattered skin lesions. However, prospective, collaborative 
studies are required to confirm this latter conclusion. PCLBCL, LT and rare patients with a 
PCFCL presenting with skin lesions on the leg appear to have a more aggressive clinical 
course, and RT should not be considered as first choice of treatment in these patients.
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Abstract 
Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20-25% of all 
primary cutaneous lymphomas. With the advent of the World Health Organization-
European Organization for Research and Treatment of Cancer (EORTC) consensus
classification for cutaneous lymphomas in 2005, uniform terminology and
classification for this rare group of neoplasms was introduced. However, staging
procedures and treatment strategies still vary between different cutaneous lymphoma
centres, which may be due to the fact that consensus recommendations for the
management of CBCL have never been published.
Based on an extensive literature search and discussions within the EORTC Cutaneous
Lymphoma Group and the International Society for Cutaneous Lymphomas, the
present report aims to provide uniform recommendations for the management of the
three main groups of CBCL. Since no systematic reviews or (randomized) controlled trials 
were available, these recommendations are mainly based on retrospective studies and small 
cohort studies. Despite these limitations, there was consensus among the members of the 
multidisciplinary expert panel that these recommendations reflect the state of the art 
management as currently practised in major cutaneous lymphoma centres. They may 
therefore contribute to uniform staging and treatment and form the basis for future clinical 
trials in patients with a CBCL.
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Introduction 
In the last two decades it has become clear that some subtypes of B-cell non-Hodgkin 
lymphoma can exclusively present in the skin. These primary cutaneous B-cell lymphomas 
(CBCL) are much less common than primary cutaneous T-cell lymphomas (CTCL) and 
represent approximately 20-25% of all primary cutaneous lymphomas.1 For many years 
there has been confusion regarding the terminology and classification of CBCL (see Table 
1), which may have come to an end with the publication of the new WHO-EORTC 
classification for cutaneous lymphomas.1 This classification distinguishes three main types 
of CBCL: primary cutaneous marginal zone B-cell lymphoma (PCMZL), primary 
cutaneous follicle centre lymphoma (PCFCL) and primary cutaneous diffuse large B-cell 
lymphoma, leg type (PCLBCL, LT). The characteristic clinical, histological and 
immunophenotypical features of these three subgroups are presented in Table 1 and 
characteristic clinical presentations in Figures 1-3. In the forthcoming update of the WHO 
classification (to be published in the WHO Blue Book Series in June 2008), PCFCL and
PCLBCL, LT will be included as separate entities, while PCMZL will be included in the 
broader category of extranodal marginal zone B-cell lymphomas.
It is generally recognized that PCMZL and PCFCL are indolent types of CBCL, which 
should not be treated primarily with systemic chemotherapy. Nonetheless, many patients 
with a PCFCL, - in particular patients with a diffuse infiltration of large cleaved cells that 
were previously classified as diffuse large B-cell lymphoma (DLBCL) in the WHO 2001 
classification2 -, are often still treated unnecessarily with systemic chemotherapy. 
Moreover, staging procedures and treatment strategies vary between different cutaneous 
lymphoma centres, which may be due to the fact that, in contrast to CTCL3;4, consensus 
guidelines for the management of CBCL have never been published.
Based on an extensive literature search and discussions at meetings of the EORTC 
Cutaneous Lymphoma Group (EORTC-CLG) and the International Society for Cutaneous 
Lymphoma (ISCL), the present report aims to provide uniform recommendations for the 
staging and treatment of the three main types of CBCL. Rare types of CBCL that 
occasionally present in the skin without detectable extracutaneous disease (e.g. 
intravascular large B-cell lymphoma and plasmablastic or lymphoblastic lymphoma) will 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Development process of recommendations 
At a meeting of the ISCL Group in March 2006 representatives of the Dutch Cutaneous 
Lymphoma Group were asked to formulate a proposal for recommendations for the 
management of CBCL. Based on the results of an extensive literature search, concept 
recommendations were made, which were discussed and agreed upon with minor 
modifications at an ISCL meeting in Buenos Aires in September 2007. The final text was 
agreed upon by an expert group of dermatologists, hematologists/oncologists and radiation 
oncologists, selected from the membership of the EORTC-CLG and ISCL group for their 
expertise in research and clinical practice of CBCL.  
Review of the literature 
A search of PubMed, EMBASE and Web of Science was conducted to identify relevant 
studies (final update 7 December 2007). Relevant articles were identified by combining 
terms and phrases related to cutaneous or skin, B-cell lymphoma(s) and treatment or 
therapy. Relevant articles were selected and reviewed by two reviewers (NJS; RW). 
Articles were selected for inclusion if they described treatment results in patients with 
CBCL or if they contained a table with clinical and follow-up data of CBCL patients, 
containing at least information on initial treatment and treatment results. Because of the low 
incidence of CBCL and the fact that (randomised) controlled trials and systematic reviews 
were not available, case reports and small retrospective cohort studies were also included. 
Papers describing other entities besides the three main groups of primary cutaneous B-cell 
lymphoma (PCMZL, PCFCL and PCLBCL, LT), papers without relevance to treatment, 
reviews merely summarizing existing literature, meeting abstracts and most non-English 
literature were excluded. Many other papers were of limited value because the type of 
CBCL was not specified or treatment results were not reported separately for different 
diagnostic subgroups. If the same cohort was described in several subsequent papers, only 
the last publication was used in our analysis. From the original 318 retrieved references, 92 
were selected for further analysis. These included 32 case reports (35%) and 60 case series 
or retrospective cohort studies including 2-5 patients (20 papers; 22%), 6-10 patients (9 
papers; 10%), 11-50 patients (23 papers; 25%) or more than 50 patients (8 studies; 9%). 
Papers were scored according to the levels of evidence as described by the Oxford Centre 
for Evidence-Based Medicine (available from: 
http://www.cebm.net/levels_of_evidence.asp. Accessed 3 December 2007). However, since 
only case reports, case series and retrospective cohorts were available and as a result all 
evidence was scored as level 4 or 5 and grades of recommendation were mostly of the D 
category, levels of evidence are not further discussed.
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Diagnosis and staging of cutaneous B-cell lymphomas 
Diagnosis
When a cutaneous B-cell lymphoma is clinically suspected, adequate histological and 
immunohistochemical studies are required to confirm or discard the diagnosis. A definite 
diagnosis can only be made on a representative biopsy of adequate length and diameter 
(preferably an excisional biopsy, but in case of punch biopsies the diameter should be at 
least 4 mm whenever possible). Besides considering the morphology of the neoplastic B-
cell population and the growth pattern of the malignant infiltrate, immunohistochemical 
studies are required to make a definite diagnosis. Since a detailed description of markers 
used in the differential diagnosis of cutaneous B-cell infiltrates is beyond the scope of this 
review, only a short-list of relevant immunostainings is provided:
 CD3, CD20 and/or CD79a for confirmation of B-cell lineage and assessment of the 
amount of admixed reactive T-cells.
 Surface and cytoplasmic immunoglobulins (sIg; cIg) on frozen and paraffin sections, 
respectively, to confirm B-cell lineage and to detect monotypic Ig expression. 
 CD35 or CD21 to visualize reactive follicles or (remnants of) dendritic networks.
 Ki-67 to determine the proliferative fraction and to aid in the differentiation between 
neoplastic and reactive follicles.5
 Bcl-2, Bcl-6, CD10, MUM-1 and FOXP1 may aid in the distinction between different 
types of CBCL, pseudo B-cell lymphoma and secondary cutaneous B-cell lymphoma 
(see Table 1).6-9 Strong expression of Bcl-2, Bcl-6 and CD10 in follicular structures 
should always raise suspicion of a systemic follicular lymphoma with secondary skin 
involvement and the presence of the interchromosomal translocation t(14;18) should be 
examined.
 In selected cases use of CD5 and cyclin D1 is useful to differentiate PCMZL (CD5-, 
cyclin D1-) from mantle cell lymphomas (CD5+, cyclin D1+) and skin localizations of 
B-cell lymphocytic leukaemia (CD5+, cyclin D1-).
Although successful application of flow cytometry in the diagnosis of CBCL has been 
reported10, it is not widely used and can not be considered as a substitute for 
immunohistochemistry. Disadvantages of this approach are the difficulties to obtain 
sufficient viable single cell suspensions, due to the vulnerability of the cutaneous B-cells, 
the lack of architectural information and the need of additional fresh tissue material. 
Demonstration of clonal IgH gene rearrangements, using the standard BIOMED-2 primers 
and protocol11-14, may be a useful aid in the diagnosis of CBCL, but the results should 




ISCL/EORTC recommendations for staging in cutaneous lymphomas other than mycosis 
fungoides/Sézary syndrome have recently been published.15 Proper clinical staging 
evaluation should begin with a complete history and review of systems (e.g. B-symptoms, 
organ-specific signs) and a thorough physical examination. Laboratory studies include a 
complete blood cell count with differential and a comprehensive blood chemistry 
measurement including lactate dehydrogenase (LDH), and in selected cases, serum 
electrophoresis to exclude a monoclonal gammopathy and/or flow cytometry on peripheral 
blood. Since an association between Borrelia burgdorferi infection has been reported in a 
significant minority of European cases of PCMZL, but not in Asian cases or cases from the 
United States16-19, in European areas with endemic B. burgdorferi infection, the presence of 
B. burgdorferi should be investigated by serology and PCR techniques on skin biopsy 
specimens. Adequate imaging studies (contrast enhanced CT-scan with or without PET, or 
whole-body integrated PET/CT15) should be performed of at least chest, abdomen and 
pelvis, and in cases of skin lesions in the head and neck area, of the neck as well. In the 
recently published ISCL/EORTC guidelines, bone marrow biopsy and aspirate are required 
in PCLBCL, LT, but considered optional in indolent CBCL (PCMZL and PCFCL).15
However, a recent study demonstrated bone marrow involvement in 22 of 193 (11%) 
patients with a follicle centre lymphoma (FCL) first presenting in the skin, as compared to 
two of 82 patients with a marginal zone lymphoma (MZL)20 In nine of these 22 FCL 
patients this was the only evidence of extracutaneous disease. The 5-year overall and 
disease-specific survivals of these nine patients were 44% and 63%, respectively, compared 
to 84% and 95% in 157 patients without extracutaneous disease. These results indicate that 
bone marrow examination should be considered as an essential part of staging procedures in 
patients with a FCL first presenting in the skin and that, from a clinical point of view, bone 
marrow examination appears to have limited value in patients with a MZL presenting in the 
skin. Since currently there is no uniform consensus whether bone marrow biopsy is 
required in follicle center lymphomas presenting in the skin, the clinician is advised to 
follow the standard of care of his or her regional practice.
Recommendations for the treatment of primary cutaneous B-cell lymphomas
The different treatment options emerging from our literature search are summarized in 
Table 2. Therapy options most often reported included radiotherapy, systemic 
chemotherapy, rituximab and excision. For the other treatment modalities relative few 
studies were available for review. Table 2 also includes therapies which are still under 
investigation as well as some therapies, for which only anecdotal reports are available. 
Most of these will not further be discussed. Cumulative complete remission (CR) and 
relapse rates for the different treatment modalities used in patients with PCMZL, PCFCL 
and PCLBCL, LT were synthesized from the reviewed literature and are provided in Table 



















































































































































































therefore not be discussed. In the following paragraphs the results of these different 
treatment options are described in more detail and recommendations for the management of 
these CBCL are formulated. 
Table 2. Overview of reported therapies for primary cutaneous B-cell lymphomas.
Therapy References
First and second-line therapies
Local radiotherapy 5;21-31;40;45;50;52-61;80;81;87;102-108
Systemic multiagent chemotherapy 21;25;28-30;40;45;52;53;56;78-81;84;85;93;104;105;109
















Table 3. Therapy results.
Cumulative studies Patients, N CR, no. (%) Relapse, no. (%)
PCMZL
Radiotherapy 132 130/132 (99%) 60/130 (46%)
Excision 75 74/75 (99%) 32/74 (43%)
Interferon alpha 8 8/8 (100%) 2/8 (25%)
Rituximab i.l. 9 8/9 (89%) 5/8 (62%)
Rituximab i.v. 3 2/3 (67%) 1/2 (50%)
Chlorambucil 14 9/14 (64%) 3/9 (33%)
Antibiotics 14 6/14 (43%) 1/5 (20%)*
Multi-agent chemotherapy 33 28/33 (85%) 16/28 (57%)
PCFCL
Radiotherapy 460 457/460 (99%) 216/457 (47%)
Multi-agent chemotherapy 104 88/104 (85%) 42/83 (51%)*
R-CHOP 2 1/2 (50%) 0/1 (0%)
Interferon alpha 7 7/7 (100%) 2/7 (29%)
Rituximab i.l. 12 10/12 (83%) 4/10 (40%)
Rituximab i.v. 28 21/28 (75%) 4/19 (21%)*
Excision 93 91/93 (98%) 36/91 (40%)
Chemoradiotherapy 7 7/7 (100%) 1/7 (14%)
PCLBCL, LT
Radiotherapy 101 89/101 (88%) 52/89 (58%)
Multi-agent chemotherapy 32 26/32 (81%) 14/24 (58%)*
R-CHOP 12 11/12 (92%) 1/11 (9%)#
Chemoradiotherapy 6 4/6 (67%) 1/2 (50%)*
Rituximab i.v. 13 5/13 (39%) 0/4 (0%)*
* Data on relapse rate were not available in all patients.
# Short follow-up period.
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Primary cutaneous marginal zone B-cell lymphoma
Radiotherapy
In the literature a total of 132 PCMZL patients are described who were treated with 
radiotherapy.21-30 In nearly all cases (130/132; 99%) a CR after initial therapy was reached. 
Sixty patients (46%) showed one or more relapses, which were mostly confined to the skin. 
Extracutaneous progression was reported in only three of 132 patients, one of whom died of 
lymphoma.26 Reported cumulative doses per irradiation field were mostly between 30 and 
45 Gy. However, doses as low as 10 Gy and as high as 50 Gy have been reported.22;29 Most 
studies included a margin of clinically normal skin in the radiation field, ranging from 1 to 
more than 5 cm, partly depending on the affected body site. 
Excision
In daily practise, surgical excision is a first choice of treatment in patients presenting with 
one or few small skin lesions. In the literature 75 patients treated with surgical excision 
have been reported.21;25;29-32 A CR was reached in all but one30 cases. However, 32 patients 
(43%) developed new skin lesions. Information whether these represent local recurrences or 
true relapses (new skin lesions at other skin sites) is not provided. In addition, no 
information was given regarding the margins of resection or whether dissemination to 
extracutaneous sites had occured. 
Interferon alpha (IFN) intralesionally (i.l.)
Only one paper describes the use of IFN in PCMZL.33 In contrast to its systemic use in 
CTCL, in this study eight patients received intralesional injections of 3 million IU, 3 times 
per week. All patients reached a CR after a median of 8 weeks (range 3-20 weeks). Two 
patients experienced a local recurrence, which went again in CR after treatment with IFN. 
No extracutaneous relapses were reported and side effects were generally mild.
Rituximab i.l. or intravenously (i.v.) 
Five reports describe the use of rituximab in PCMZL.34-38 In three patients it was 
administered systemically (375 mg/m2 i.v. once weekly, for 4 or 8 weeks; two out of these 
three patients had multifocal disease)35;36;38, and in nine patients intralesionally (5-30 mg 
once or 3x/week;8/9 patients had  4 skin lesions).34;36;37 Two out of three (67%) 
systemically treated patients and eight out of nine (89%) intralesionally treated patients 
reached a CR, with the remaining patients reaching a partial remission (total response rates 
100%). Relapse rates were 50% (1/2) and 62% (5/8), respectively, and no extracutaneous 
relapses were reported.
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Single agent and combination chemotherapy
With respect to single agent chemotherapy, four reports describe the results of 
chlorambucil, a nitrogen mustard derivative, which has been used for many years in the 
treatment of low-grade systemic non-Hodgkin’s lymphomas and leukemias. There was a 
total number of 14 patients with a PCMZL in these studies, all with multifocal skin 
lesions.23;25;31;39 The response rate was 100% with a CR in nine patients (64%) and a partial 
remission in the other five patients. Of the nine patients with a CR, three patients showed 
relapses (33%), one of whom also with extracutaneous localizations. Reports on other 
agents used in indolent B-cell NHL, such as fludarabine and 2-chlorodeoxyadenosine (2-
CDA) are lacking.
Multiagent chemotherapy (mostly CHOP) was administered to 33 PCMZL patients 
reported in the literature, again mostly patients with multifocal skin lesions.21;25;30;40
Complete remission rate was 85% and a relapse rate of 57% was found. 
Antibiotics 
Analogous to the treatment of gastric MALT lymphomas with antibiotic therapy to 
eradicate Helicobacter pylori41-43, recent reviews suggest that PCMZL associated with B. 
burgdorferi infection should first be treated with antibiotics before more aggressive 
therapies are employed.44 However, the efficacy of antibiotic treatment in B. burgdorferi-
associated PCMZL is poorly documented.29;31;45-48 Six of 14 (43%) reported patients 
achieved CR after various antibiotic regimens. Data on eight patients for whom antibiotic 
treatment was specified, suggest that systemic treatment with cephalosporins is superior to 
oral treatment with high dose tetracyclins.
Recommendations (see Table  4.)
Patients presenting with solitary or few scattered skin lesions can best be treated with local 
radiotherapy (20-36 Gy) or excision. For patients presenting with disseminated skin lesions 
several management strategies can be considered. A strategy not supported by data from 
literature, but generally practised by the expert panel members as the management of 
choice, is a wait and see strategy, similar to what is often used for indolent non-cutaneous 
B-cell lymphomas and leukemias. This strategy implies that patients are carefully followed 
and only symptomatic lesions are treated (“treat as needed” concept). Individual,
symptomatic skin lesions can be treated with surgery, topical or intralesional steroids or 
low dose radiotherapy. Intralesional administration of IFN or rituximab may be interesting 
alternatives, but further studies are required.
In patients with very extensive skin lesions, chlorambucil is still often used in European 
centres, - in particular in older patients and for a limited period of time (maximal 3 months) 
-, but it is uncommonly used in the United States. Other single agent or combination 
chemotherapy regimens appropriate for systemic low-grade B-cell lymphomas may be 
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considered, but published results are not available. Alternatively, systemic rituximab can be 
considered. Multi-agent chemotherapy is rarely indicated in this type of CBCL.
Cutaneous relapses do not signify a worse prognosis and can be treated in the same way as 
the initial skin lesions.  
Theoretically, it is attractive to suggest that PCMZL associated with a B. burgdorferi
infection should first be treated with antibiotics before other therapies are employed. 
However, although some CR have been reported, in particular in patients treated with 
systemic cephalosporins, additional studies are required to establish which patients may 
benefit from antibiotic treatment and to assess which type, dose and duration of antibiotic 
treatment should be recommended.
Primary cutaneous follicle centre lymphoma
Radiotherapy 
Already in 1951 Crosti described 7 cases of “reticulohistiocytoma of the dorsum” that were 
markedly sensitive to radiation therapy.49 This entity was later reclassified as PCFCL.50;51
Most recent reports on treatment of PCFCL describe local radiotherapy as the first choice 
of treatment, since it is highly effective and it has few side effects. In the literature we 
found a total number of 460 PCFCL patients initially treated with RT.5;22;23;26;27;29;30;45;50;52-61
These were mostly patients with solitary or localized skin lesions, but some reports also 
include patients with multifocal skin disease, necessitating the use of multiple radiation 
fields.22;26;27;58 In one study specifically addressing such patients, it was found that 
radiotherapy of all visible skin lesions was equally effective as treatment with multi-agent 
chemotherapy.40 A CR was reached in nearly all cases, irrespective of the extent of the 
disease (457/460; 99%). Three major studies on RT in PCFCL (combined including 147 
patients; median follow-up 52, 62 and 41 months, respectively) report a relapse rate of 
approximately 30%22;26;27, which contrasts with the 76% in an Italian study (104 patients; 
median follow-up, 62 months).58 This latter group also reported in-field and marginal 
recurrences which were not seen in the other studies. These differences might be due to the 
variance in techniques used and, most important, the margins of healthy looking skin 
included in the radiation field (ranging from 0,5 to more than 5 cm.). The cumulative dose 
per irradiation field was generally more than 30 Gy (range, 20-54 Gy).
Excision 
A total of 93 patients was found in the literature that were initially treated with complete 
surgical excision.5;28-30;53-55;60 Most patients reached CR (91/93; 98%) and less than half of 
them (36/91; 40%) developed a skin relapse. No details are provided concerning excision 
margins or specific sites of local recurrence or relapse at distant skin sites. 
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Interferon alpha (IFN) i.l. 
Intralesional treatment of PCFCL patients with IFN has been reported in only seven cases, 
with dosages varying from 1 million IU, 3x per week to 6 million IU, 3x per week for 
larger lesions.46;62-64 All seven patients reached a CR. Two patients experiencing a clinical 
relapse were again successfully treated with a second course of IFN.62 However, since the 
follow-up periods were rather short, no firm conclusions regarding relapse rate or long-term 
efficacy can be made. 
Rituximab i.l. + i.v  
Both intralesional and systemic rituximab have been used in PCFCL. Ten of 12 patients 
treated intralesionally reached CR and the other two patients had a partial remission.34;36;65-
67 Dosages and treatment regimens varied between 10 and 30 mg per lesion per application 
for two or three times a week. Duration of treatment was more variable, ranging from one 
or two injections in total, to treatment for up to six months. Four of 10 patients with CR 
developed new skin lesions; two in the originally treated site and two at distant skin sites. 
No extracutaneous relapses were seen. 
The 28 patients systemically treated with rituximab, all received doses of 375 mg i.v./m2
body surface area once weekly.34-36;68-77 Duration of treatment was mostly four weeks, but 
ranged from one to eight weeks. Twenty-one patients reached CR, six patients showed 
partial remission and one patient76 had progressive disease, but went into complete 
remission following eight CHOP courses. In four of the 21 patients with CR, relapses were 
reported and these were all confined to the skin. 
Multi-agent chemotherapy 
Relatively few data exist in the literature concerning treatment of PCFCL patients with 
multi-agent chemotherapy, whilst one would expect that many of these patients, -in 
particular those with a diffuse growth pattern, classified as DLBCL according to the WHO 
classification -, were treated in this way. Moreover, two of the largest studies could not be 
used for analysis since they describe mixed groups of patients based on older classification 
schemes.78;79 Cumulative data from eight papers on 104 patients show a CR rate of 85% 
(88/104 patients) and a relapse rate of 48% (42/88 patients).28;30;40;52;53;56;80;81 These were 
mostly patients with disseminated cutaneous lesions or heavy tumour burden. Most patients 
had been treated with CHOP or CHOP-like courses, and only five patients with COP, 
which however was reported to be less effective.78;80
In DLBCL presenting with localised disease (Ann Arbor stage I-E) a combination of 
chemotherapy (3-4 cycles of CHOP) and involved field radiotherapy (IFRT) has been 
suggested to be superior to one of either modalities alone.79 Reports on this combined 
treatment in patients with PCFCL are few.28;52;54-56 Cumulative data on seven patients show 
a CR in all patients, with a reported relapse in one of them.
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While a combination of rituximab and CHOP (R-CHOP) has become standard treatment for 
DLBCL for more than five years82;83 and many cases of PCFCL would have been classified 
as DLBCL using the WHO 2001 classification, only two patients with PCFCL who were 
treated with R-CHOP have been published thus far. One patient went into CR and had no 
relapse in the following 12 months.84 The second patient had only a PR following six cycles 
of R-CHOP. Further progression of the skin lesions was noted 1.5 years later, and single 
agent treatment with rituximab resulted in a CR, which was ongoing for over 19 months.70
A third patient, treated with a combination of cyclophosphamide and rituximab, showed a 
reduction of less than 30% of skin lesions.85
Recommendations (see Table 4)
In patients presenting with solitary or localized skin lesions, RT with a dose of at least 30 
Gy and a margin of clinically uninvolved skin of at least 1-1,5 cm, is the preferred mode of 
treatment. Solitary lesions that are small and well-demarcated can be treated with surgical 
excision. 
In patients with an indolent PCFCL presenting with few scattered lesions both radiotherapy 
of all visible skin lesions as well as a wait and see policy with treatment of only 
symptomatic skin lesions, similar as recommended for PCMZL, can be considered for 
initial management. In patients with very extensive skin lesions systemic rituximab is the 
first choice of treatment. Combination chemotherapy (R-COP; R-CHOP) should be 
considered only in exceptional cases, such as patients with progressive disease not 
responding to rituximab or patients developing extracutaneous disease.
Relapses occur in approximately 30% of patients, are mostly confined to the skin and do 
not signify a worse prognosis. For the treatment of cutaneous relapses a similar approach as 
for the initial skin lesions is recommended. Also in these cases multi-agent chemotherapy is 
rarely indicated. 
Finally, recent studies showed that PCFCL presenting on the leg(s) have a considerably 
worse prognosis, comparable to that of PCLBCL, LT.9;86 Although reports are few, it seems 
safe to propose that such patients should receive the same treatment as recommended for 
PCLBCL, LT (see below). 
Primary cutaneous diffuse large B-cell lymphoma, leg type
Radiotherapy
Radiotherapy is less effective in PCLBCL, LT than in the indolent CBCL. The CR rate in 
101 reported cases was 88% (89/101 patients) and the relapse rate was 58% (52/89 
patients), while also in-field and marginal recurrences have been 
reported.22;23;26;27;29;30;56;58;87  Extracutaneous progression was reported in approximately 
30% of patients. 
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Rituximab i.v. 
Treatment with rituximab i.v. as single agent therapy (375 mg i.v./m2 body surface area 
once weekly for four to eight weeks) is reported in 13 patients, in seven of them as second 
or third line treatment.35;76;77;88-92 A CR was obtained in only five of 13 patients, including 
three of six patients, who received rituximab as initial treatment. None of the four patients 
with CR of whom follow-up was reported had a relapse, but the duration of follow-up was 
short (median seven months).  
Multi-agent chemotherapy
Recent reviews suggest that PCLBCL, LT  should be treated as systemic DLBCL with 
multi-agent chemotherapy with or without rituximab.1;44 However, only 32 patients 
receiving CHOP(-like) (n = 29) or COP (n = 3) have been reported.29;30;40;45;56;80;81;93
Collectively, 26 of 32 patients (81%) reached a CR and 14 of 26 CR patients (54%) had a 
relapse. A combination of CHOP and IFRT was used in a further six patients and resulted 
in a CR in four of them.28;45;94;95
One recent study describes 12 patients treated with various combinations of anthracycline-
containg chemotherapies and rituximab. All but one patient reached a complete remission 
(92%) and only one patient relapsed (9%). The authors suggest that patients with PCLBCL, 
LT treated with various combinations of age-adapted, anthracycline-containing 
chemotherapies and rituximab, have a better outcome than patients receiving other 
treatments, however, follow-up of the group treated with chemotherapy and rituximab was 
insufficient (mean follow-up period less than two years) to determine a statistically 
significant difference.96 In addition, another report described a CR in one of two patients 
treated with cyclophosphamide and rituximab.85
Recommendations (see Table 4.)
Since PCLBCL, LT patients have morphological, phenotypical  and molecular genetic 
features as well as a clinical behaviour similar to that of systemic DLBCL, they should be 
treated consistently. Nowadays, R-CHOP with or without IFRT is considered as the first 
line of treatment in these lymphomas, but the efficacy of this approach in patients with 
PCLBCL, LT is still poorly documented. In case the condition of the patient does not allow 
such an aggressive treatment, local radiotherapy of all visible skin lesions or perhaps 
rituximab as single agent therapy can be considered. Whether radiotherapy should be 
considered as first choice of treatment in patients presenting with a small solitary tumour is 
a matter of debate. In order to gain more knowledge on the most favourable treatment for 
this rare patient group with a poor prognosis, it is important to treat patients in the setting of 
controlled clinical trials.
As there are insufficient studies on relapsed PCLBCL, LT it is recommended that these 
patients be treated as relapsed DLBCL, using local protocols.  
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Table 4. Recommendations for initial management of the 3 main types of CBCL.
Disease type and 
extent First line therapy Alternative therapies
PCMZL













 IFN alpha i.l.
 Rituximab i.l.
 Topical or intralesional 
steroids
PCFCL
Solitary/ localized  Local 
radiotherapy
 Excision








Solitary/ localized  R-CHOP +/- IFRT  Local radiotherapy
 Rituximab i.v.
Multifocal  R-CHOP  Rituximab i.v.
1  in case of evidence for B. burgdorferi infection.
2 or other single or combination regimens appropriate for low-grade B-cell lymphomas.
3  in exceptional cases or for patients developing extracutaneous disease.
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Conclusion
Based on an extensive review of available literature and discussions within the EORTC and 
ISCL groups, the present report provides consensus recommendations for the management 
of CBCL. It should be emphasized that, since systematic reviews and (randomized) 
controlled trials were not available, the treatment recommendations are mainly based on 
retrospective studies and small cohort series. In addition, in most of these studies 
information on relapse-free survival or progression-free survival was not included and in 
many studies follow-up was too short to draw conclusions on long-term efficacy. Despite 
these limitations, there was consensus among the members of the multidisciplinary expert 
panel that these recommendations reflect the state of the art treatment of CBCL, as 
currently practised in major cutaneous lymphoma centres. These recommendations may 
therefore contribute to uniform staging and treatment and may prevent in particular 
overtreatment of subgroups of CBCL patients. These recommendations may also guide the 
design of future clinical trials in CBCL, which are highly necessary and, in view of the 
rarity of these conditions, should be multicenter studies, preferably within the frame work 
of the EORTC Cutaneous Lymphoma Group and/or ISCL. Trials most often suggested by 
the expert panel members were, rituximab against current best practice (wait and see 
strategy with radiotherapy when needed) in both PCMZL and PCFCL, and radiotherapy 
versus R-CHOP + IFRT, in patients with PCLBCL, LT presenting with a solitary lesion. In 
addition, comparison between systemic and intralesional treatment with rituximab in 
PCFCL could be of interest, since also in patients treated intralesionally a complete 
disappearance of B-cells in the peripheral blood has been noted, indicating a systemic 
effect.34;65 In selected cases intralesional rituximab might prove to be an equally effective, 
but much cheaper alternative for systemic rituximab. Cutaneous lymphoma groups with 
experience in treating B. burgdorferi-associated PCMZL with (systemic) antibiotics are 
encouraged to publish their treatment results, either positive or negative, to find out if 
further studies are required. Controlled multicenter studies are also required to assess the 
efficacy of new therapies, such as yttrium-90 ibritumomab tiuxetan (Zevalin®) or 131I-
tositumomab (Bexxar®) radioimmunotherapy97 and pegylated liposomal doxorubicin98
(plus rituximab) in PCLBCL, LT and gene therapy with adenovirus-mediated transfer of 
IFN-gamma in PCMZL and PCMZL.99-101 Today, only the last mentioned approach is 
investigated in a prospective trial. Finally, patients with a CBCL can best be managed in 
centres where a close collaboration between dermatologist, haematologist/oncologist and 
radiation oncologist exists. This is probably the most important recommendation and the 
best guarantee for optimal management.
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In the last decade there has been an ongoing debate whether the EORTC or the WHO 
classification should be used for classification of primary cutaneous B-cell lymphomas 
(CBCL). The discrepant points of view were not only a matter of academic dispute, but also 
had major therapeutic consequences. With the publication of the WHO-EORTC 
classification in 2005, this controversy may have come to an end. However, a number of 
outstanding issues remained, that needed to be addressed.
The main issues concerned (1) the clinical usefulness of the WHO-EORTC 
classification in daily practice, (2) the validity of prognostic parameters reported in 
previous studies and identified in patient groups classified according to previously used 
classification schemes and (3) optimal management for the different types of CBCL as 
defined in the WHO-EORTC classification. In this concluding chapter, these three issues 
will be discussed based on the data described in this thesis and data from the literature. 
The WHO-EORTC classification for CBCL in daily practice
In Chapter 2, the clinical significance of the WHO-EORTC classification was assessed on 
300 CBCL cases, present in the database of the Dutch Cutaneous Lymphoma Group 
(DCLG), and compared to the previously used EORTC and WHO classification schemes. 
Furthermore, we aimed to more clearly define which cases should be assigned to the group 
of primary cutaneous diffuse large B-cell lymphoma, other (PCLBCL, other). 
Using the criteria of the WHO- EORTC classification, primary cutaneous marginal 
zone B-cell lymphoma (PCMZL) and primary cutaneous follicle centre lymphoma 
(PCFCL) showed a 5-year disease-specific survival (DSS) of 98% and 95%, respectively, 
whereas primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT) had a 
5-year DSS of only 50%. These results are in agreement with the results of recent studies 
and confirm that the new WHO-EORTC classification adequately distinguishes between 
CBCL with an indolent and CBCL with a more aggressive clinical behaviour.1-3 Most 
patients with PCMZL presented with multifocal skin lesions mainly on the trunk and 
extremities. Although the frequency of skin relapses was high and extracutaneous 
dissemination was observed in 9% of patients, only one patient died due to lymphoma. In 
the group of PCFCL, most patients characteristically presented with skin lesions on the 
head or trunk and only a small minority (6%) presented with lesions on the leg(s). 
Expression of the so called, activated B-cell (ABC) markers, Bcl-2, MUM-1 and FOXP1, 
was found in only 11%, 10% and 4% of cases respectively. Extracutaneous progression was 
seen in 11% of patients, while ultimately 5% of patients died due to their lymphoma. 
Patients with PCLBCL, LT most often presented with lesions on the leg(s) and only 12% of  
patients had skin lesions restricted to another skin site. The neoplastic B-cells strongly 
expressed Bcl-2, MUM-1 and FOXP1 in the majority of cases (90%, 90% and 81% 
respectively), both in patients with lesions on the legs and elsewhere. This group showed a 
high rate of extracutaneous progression (47%) and 45% of patients died of lymphoma.
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In contrast to the EORTC classification, in which differentiation between primary 
cutaneous follicle centre cell lymphoma (PCFCCL) and primary cutaneous large B-cell 
lymphoma of the leg (PCLBCL-leg) was based on site (non-leg or leg), in the WHO-
EORTC differentiation between PCFCL and PCLBCL,LT is based primarily on cell 
morphology, i.e. cleaved cells (centrocytes) versus noncleaved or round cells (centroblasts 
and immunoblasts). Differentiation on the basis of morphology is known to be associated 
with a considerable inter-observer variation.4;5 While cases with a clear (partly) follicular 
growth pattern will be easily classified as PCFCL, in cases with a diffuse growth pattern 
this classification might be more difficult. In such difficult cases, the presence of a 
considerable proportion of admixed T cells, the presence of a stromal reaction as well as 
demonstration of (remnants of) follicular dendritic cell networks by staining with 
appropriate antibodies (CD35 or CD21) may serve as useful additional criteria suggesting a 
diagnosis of PCFCL.6 Moreover, since it was found that most PCLBCL, LT cases 
expressed Bcl-2, MUM-1 and FOXP1, this phenotypic profile might also be a useful 
adjunct, supporting a diagnosis of PCLBCL, LT.1;2;6 However, since Bcl-2, MUM-1, and to 
a lesser extent FOXP1 are also expressed by a small minority of PCFCL and a small 
minority of PCLBCL, LT do not express these markers, they cannot be used as a golden 
standard to differentiate between both conditions.
Comparing the three classification schemes demonstrated no important differences 
in the classification of PCMZL and PCFCL with a follicular or follicular and diffuse 
growth pattern. However, 65% of cases classified as diffuse large B-cell lymphoma 
(DLBCL) using the WHO classification, were reclassified as PCFCL using the WHO-
EORTC scheme, which implies that these patients can be managed by local therapies 
instead of more aggressive systemic therapies. This illustrates that the WHO-EORTC 
classification is a major step forward as compared to the WHO classification and that it 
contributes to a more appropriate treatment in patients with CBCL. The reclassification of 
10% of cases formerly classified by the EORTC classification, concerned seven PCFCCL 
patients with a predominant round-cell morphology, that were now classified as PCLBCL, 
LT and nine PCLBCL-leg patients with a cleaved-cell morphology that were now included 
as PCFCL. For the seven PCFCCL patients with round-cell morphology this 
reclassification proved clinically relevant since they showed the same intermediate 
prognosis as other cases with the same morphology presenting on the leg. However, the 
reclassification of the nine cleaved-cell cases presenting on the leg as PCFCL proved less 
fortunate, since they showed a significantly worse prognosis as compared to PCFCL cases 
presenting with skin lesions on other body regions.
Recent studies used the term PCLBCL, other in different ways. Some authors 
assigned all cases with a predominance of large round cells without Bcl-2 expression to the 
group of PCLBCL, other2;7, while we and others classified such cases as PCLBCL, LT, 
irrespective of the location of skin lesions and Bcl-2 expression.3;6 In our study, comparison 
of Bcl-2–positive and Bcl-2–negative PCLBCL, LT showed no significant difference in 5-
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year DSS or 5-year overall survival (OS), which is consistent with the results of Kodama et 
al.2 Similarly in both studies, no significant differences in 5-year OS and DSS were found 
between PCLBCL, LT with or without expression of MUM-1 or FOXP1. These data 
indicate that distinction between patients with or without expression of Bcl-2, MUM-1, or 
FOXP1 is not useful, and that categorization of Bcl-2–negative patients as PCLBCL, other, 
as suggested previously2;7, is not justified. This term should be reserved for rare 
morphological variants of diffuse CBCL, that do not fit the criteria of either PCFCL or 
PCLBCL, LT.
Prognostic factors for the newly defined CBCL groups
Prognostic factors for CBCL described in previous studies, are currently not useful 
anymore or need to be confirmed, since they were identified on patient groups defined with 
older classification systems or by studying mixed diagnostic populations. Prognostic factors 
were studied in three chapters of this thesis. 
Clinical, histological and immunophenotypical markers: a multivariate analysis
In Chapter 2 we aimed to define prognostic parameters within the redefined 
categories PCFCL and PCLBCL, LT. We analyzed various clinical, histological and 
immunophenotypical markers using univariate and multivariate analyses. 
Both in the total group of PCFCL and in the group of PCFCL with a diffuse 
infiltrate of large cleaved cells, patients presenting with skin lesions on the leg(s), had a 
significantly worse prognosis than PCFCL presenting at other sites. This finding is 
consistent with other recent studies and implies that within this entity further distinction 
should be made based on the site of presentation.2;4;7 However, since these results are based 
on a relatively small number of PCFCL patients with lesions on the leg, this finding needs 
further validation.
Expression of Bcl-2, MUM-1 and FOXP1 was not associated with prognosis in 
PCFCL cases with a diffuse growth pattern. However, in the total group of PCFCL, both 
weak and strong expression of FOXP1 was associated with an inferior prognosis as 
compared to patients without expression of FOXP1. While in CBCL this marker has been 
reported to be associated with a round cell morphology, i.e. a diagnosis of PCLBCL, LT, 
prognostic significance within one of the CBCL entities has not been described so far. In 
systemic DLBCL, it is a matter of debate whether FOXP1 is associated with a bad 
prognosis or not.8-10 These contradictory results might be explained by recently reported 
findings, describing that the JC12 monoclonal antibody, used to determine FOXP1 protein 
expression, does not distinguish between the full-length FOXP1 protein and smaller 
isoforms, whilst it appears that these smaller FOXP1 isoforms, rather than the full-length 
protein, have a potentially oncogenic role in B-cell non-Hodgkin lymphomas.11 The exact 
role and prognostic significance of this marker in PCFCL needs further clarification. Other 
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parameters, such as age, extent of skin lesions or growth pattern did not have independent 
prognostic significance. 
In the PCLBCL, LT group localization of skin lesions or presence or absence of 
Bcl-2, MUM-1 or FOXP1 was not associated with prognosis. While in univariate analysis 
of OS both age and extent of skin lesions were associated with a poor prognosis, in 
multivariate analysis no independent prognostic markers could be identified.
The TNM classification system for primary cutaneous lymphomas other than mycosis 
fungoides (MF) and Sézary syndrome (SS)
In 2007 a new clinical staging system was proposed for primary cutaneous 
lymphoma other than MF and SS.12 This TNM based system was meant to document extent 
of disease in a consistent matter, thereby facilitating comparison between different research 
centres and study populations. At the time of publication it was unknown if the system had 
prognostic significance in CBCL. In Chapter 4 we applied this system to the 300 CBCL 
that had been reclassified according to the WHO-EORTC classification, described in 
Chapter 2. The results of Chapter 4 show that the TNM system can easily be applied to 
the three main groups of CBCL. With regard to prognostic significance, it was found that 
increasing T-score was associated with decreased survival in the group of PCLBCL, LT. 
Although the association was not statistically significant, this is in accordance with two 
other recent reports on PCLBCL, LT. These studies report a better prognosis for PCLBCL, 
LT patients presenting with a solitary tumour as compared to patients presenting with 
multiple tumours on one or both leg(s).3;4 These results are also in line with the findings 
described in Chapter 2. Here we found extent of skin lesions to be associated with an 
unfavourable prognosis only in univariate analysis. For both indolent groups of CBCL, 
PCMZL and PCFCL, the TNM classification did not provide prognostic significance. 
In addition, we compared the proposed TNM classification system with the 
scoring of the DCLG, which has been in use for many years and was used to report disease 
extent in the study described in Chapter 2. There was a discrepancy in the classification of 
20 cases, all indolent types of CBCL. This concerned cases with multiple skin lesions at 
two contiguous body sites. As there is no anatomical or biological relation between such 
separate lesions, in the DCLG system such lesions are classified as multifocal or 
generalized disease. However, as the T3 category in the TNM system is defined as 
involvement of two non-contiguous body regions or three or more body regions, such cases 
are classified as T2, which denotes regional skin involvement. In both indolent types of 
lymphoma, classification as T2 is of minor clinical importance, since they can be treated 
with non-aggressive therapies, irrespective of disease extent. However, in other, more 
aggressive cutaneous lymphomas this discrepant classification of multiple distant skin 
lesions restricted to two adjacent skin sites as T2 might have important therapeutic 
consequences. Since in our study the staging of PCLBCL, LT did not show any 
discrepancies between both systems, the applicability of the definitions for T2 and T3 
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should be evaluated in other cohorts of (more aggressive) cutaneous lymphomas, in order to 
avoid undesirable therapeutic consequences.
Inactivation of CDKN2a as a prognostic marker in PCLBCL, LT
A recent study suggested inactivation of CDKN2A as a prognostic marker in the 
PCLBCL, LT group.13 Since this was only investigated in a small number of cases, we 
sought to confirm these findings on a larger patient group. For that purpose, we needed a 
technique that could be applied on DNA derived from formalin-fixed paraffin-embedded 
(FFPE) material, since this is more readily available. We tested a recently described 
technique, called Multiplex Ligation-dependent Probe Amplification (MLPA), that was 
reported to be less sensitive to DNA degradation and shows reliable results when applied to 
DNA derived from FFPE material.14-17 Indeed, we found that comparison between fresh-
frozen and FFPE material obtained from the same tumour in two patients, showed identical 
results. In an EORTC Cutaneous Lymphoma Group (CLG) multicentre study, described in 
Chapter 3, we analyzed tumour DNA of 64 PCLBCL, LT patients, which is the largest 
group described so far. We were able to confirm inactivation of CDKN2A in a large part 
(75%) of PCLBCL, LT patients, which was correlated with reduced survival (5-year DSS 
for patients with versus without inactivation of CDKN2A: 43% versus 70%, respectively). 
However, our results were not mutually exclusive, in the sense that the study group 
contained patients with inactivation of CDKN2A that had a good prognosis, but more 
importantly, it contained five patients (8% of the total study group) that did not show 
aberrations in CDKN2A but nonetheless died of their lymphoma. The latter patients run the 
risk of being undertreated when management would be solely based on CDKN2A status. 
So, while inactivation of this gene is associated with a worse prognosis, caution is 
warranted before these results are incorporated into clinical decision making. Regardless of 
these results, MLPA has proven to be a valuable technique providing new possibilities for 
molecular studies on larger patient groups of rare diseases, using the candidate gene 
approach. 
In summary, the result of Chapters 2, 3 and 4 have not provided an independent 
prognostic marker for PCLBCL, LT which is useful at the time of diagnosis. It seems 
worthwhile to further investigate other possible prognostic markers for this rare group, by 
exploring newer genetic and epigenetic parameters. For instance, new promising research in 
the field of cancer prognostication is formed by studying microRNAs. It has been suggested 
that microRNA expression can distinguish between the germinal centre B-cell (GCB)-like 
and the activated B-cell (ABC)-like subtypes of DLBCL.18 More recently it was shown that 
elevated levels of tumour-associated microRNAs can be detected in the serum of patients 
with DLBCL and that specific microRNAs may have prognostic relevance.19 Since 
microRNAs proof to be relatively resistant to RNase degradation and can be successfully 
isolated from FFPE tissues18, they might form an ideal target for studies in CBCL samples. 
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Analysis of microRNAs in patient serum may provide new, non-invasive possibilities for 
finding relevant prognostic factors. 
Management and treatment of patients with a (primary) cutaneous B-cell lymphoma.
Staging 
A diagnosis of primary cutaneous lymphoma can only be made after adequate 
staging investigations have been conducted. However, whether or not bone marrow 
biopsies should be performed routinely in patients with skin lesions that show histological 
features consistent with an indolent lymphoma has recently been debated.12 Since there are 
no studies that have addressed this question for this particular group of lymphomas, in the 
study described in Chapter 5 we evaluated the results of bone marrow examinations in a 
large group of patients who presented with skin tumours, histologically suggestive of an 
indolent B-cell lymphoma, either marginal zone lymphoma (MZL) or follicle centre 
lymphoma (FCL). 
In the total group of 275 patients, 24 patients (9%)  showed a positive bone 
marrow histology, while in 10 patients (4%; one MZL and nine FCL) this was the only 
evidence of extracutaneous disease. If bone marrow examination had not been performed, 
these 10 patients would have been wrongfully classified as CBCL. For patients with a 
histology of MZL the clinical consequences of this “misdiagnosis” are expected to be 
limited, since treatment of MZL with skin lesions and isolated bone marrow involvement 
will not be different from that of MZL presenting with only skin involvement (i.e. 
PCMZL). However, the nine patients with the histologic features of a FCL and isolated 
bone marrow involvement had a significantly worse prognosis as compared to genuine 
PCFCL (5-year DSS 63% versus 95% respectively), which may have therapeutic 
consequences. In summary, the results of the study showed that bone marrow investigation 
is an essential component of the staging procedure in patients with an FCL first presenting 
in the skin and that bone marrow examination appears to have limited value in patients with 
MZL presenting in the skin. 
These conclusions are in line with other staging recommendations such as the most 
recent National Comprehensive Cancer Network (NCCN) clinical practice guidelines 
(version 2.2008). In these guidelines, bone marrow investigation is considered essential in 
indolent follicular lymphomas (FL), while in extranodal MZL (including PCMZL) it is only 
considered useful in selected cases. Interestingly, in previous versions of the NCCN 
guidelines (versions 2.2006, 1.2007 and 3.2007), also bone marrow examination in indolent 
FL was only considered useful in selected cases. In line with these previous NCCN 
guidelines, but not substantiated by any published data, some cutaneous lymphoma centres 
in the United States still argue that bone marrow examination in FCL patients should be 
considered optional and should only be performed in selected cases, e.g. patients with other 
positive staging assessments. Since survival of these patients is significantly different and 
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they may thus require a different management strategy, this outstanding question needs 
further clarification. 
Treatment
In Chapters 6 and 7 we evaluated the results of radiotherapy in the newly defined 
groups of CBCL and subsequently aimed to provide consensus recommendations for the 
management of these diseases. 
Local radiotherapy (RT) is a well known and effective treatment modality in the 
field of CBCL. It is widely given to patients with indolent CBCL with curative intent. Since 
it was expected that a number of patients would be assigned to a different prognostic 
category, using the criteria of the new WHO-EORTC classification, we sought to evaluate 
the results of this treatment in the newly defined categories. The results, described in 
Chapter 6, show that the large majority of tumours is very sensitive to RT. All but two of 
153 patients (99%) responded to initial RT with a complete remission (CR). The two 
patients that did not reach CR were both PCLBCL, LT patients. Relapse rates for PCMZL, 
PCFCL and PCLBCL, LT were 60%, 29% and 64% and the 5-year DSS was 95%, 97% 
and 59% respectively. PCFCL patients who presented with skin lesions on the leg(s) had a 
higher relapse rate (63%) and a much lower 5-year DSS (44%) as compared to PCFCL 
patients presenting with skin lesions at other sites (relapse rate 25% and 5-year DSS 99%). 
In summary, the results of this large retrospective study indicate that RT is a safe 
and effective treatment for patients with PCMZL and PCFCL with solitary or localized skin 
lesions. Patients with multifocal skin disease showed a tendency towards higher relapse rate 
(PCMZL and PCFCL) and extracutaneous dissemination (PCFCL), suggesting that other 
treatment modalities might be considered in such patients. Moreover, for PCFCL patients 
presenting with skin lesions on the leg and PCLBCL, LT patients, RT should not be the 
first choice of treatment.
For the paper described in Chapter 7, we integrated the results of Chapters 4, 5 
and 6 and performed an extensive literature study. Together with the results of discussions 
among a multidisciplinary group of dermatologists, haematologists/oncologists and 
radiation oncologists , selected from the International Society of Cutaneous Lymphoma 
(ISCL) and the EORTC Cutaneous Lymphoma Group (EORTC-CLG), we were able to 
formulate consensus recommendations for the management of the three main types of 
CBCL, which are summarized in Table 4 of Chapter 7. Major limitations in reviewing the 
literature on the treatment of CBCL were that (1) there was a complete lack of systematic 
reviews and large (randomized) controlled trials, (2) information on relapse-free survival or 
progression –free survival was often not included and (3) in many studies follow-up was 
too short to draw conclusions on long-term efficacy. Moreover, most of the reported studies 
so far have been based on formerly used classification schemes or heterogeneous study 
groups of different types of CBCL. Despite these limitations, there was consensus among 
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the members of the multidisciplinary expert panel that these recommendations reflect the 
state of the art management as currently practised in major cutaneous lymphoma centres. 
In brief, the main conclusions from Chapter 7 are, that for both types of indolent 
CBCL with solitary or localized disease, non-aggressive therapies such as excision or local 
RT can be applied. In PCMZL patients with multifocal or generalized skin lesions, a wait-
and-see policy seems justified. In contrast, patients with PCLBCL, LT follow a more 
aggressive clinical course and should be treated accordingly.
Regarding PCFCL patients with generalized skin lesions, optimal treatment 
remains to be determined. Currently employed management strategies vary from a wait-
and-see policy to RT of all visible skin lesions, while multi-agent chemotherapy is only 
considered in exceptional cases. Apart from RT, favourable results have recently been 
described for both intralesional and intravenous administration of rituximab in the treatment 
of CBCL.20-25 Rituximab is a chimeric (human-mouse) monoclonal antibody directed 
against the CD20 molecule present on the surface of all mature B-cells. Binding of 
rituximab to the B-cells expressing CD20, results in the elimination of all B-cells in the 
body. Systemic use of this agent has improved outcome rates in nodal FL and DLBCL 
significantly. 26-30 It seems interesting to explore the long-term efficacy of this agent in 
generalized PCFCL. Moreover, comparison between systemic and intralesional treatment 
deserves further investigation, since also in patients treated intralesionally a complete 
disappearance of B-cells in the peripheral blood has been noted, indicating a systemic 
effect.20;31 Thus, intralesional rituximab might prove to be an equally effective, but much 
cheaper alternative for systemic rituximab in PCFCL patients with extensive skin lesions.
 Besides its use in generalized PCFCL, the addition of rituximab to the standard 
chemotherapy regiments in PCLBCL, LT warrant future controlled trials in order to 
confirm recent promising findings.3;32 Controlled multicentre studies are also required to 
assess the efficacy of several other new therapies, such as intralesional interferon alpha for 
indolent CBCL33-36, yttrium-90 ibritumomab tiuxetan (Zevalin®) or 131I-tositumomab
(Bexxar®) radioimmunotherapy37, pegylated liposomal doxorubicin38(plus rituximab) and 
gene therapy with adenovirus-mediated transfer of IFN-gamma.39-41
Concluding remarks and future perspectives
In summary, the WHO-EORTC proved clinically very relevant and delineates distinct 
disease entities with different prognoses. It is therefore fortunate that both PCFCL and 
PCLBCL, LT will be incorporated as new distinct disease entities into the updated WHO 
classification for tumours of hematopoietic and lymphoid tissues, which will be published 
in 2008. PCMZL is incorporated into the broad category of extranodal marginal zone 
lymphomas, which is unfortunate in view of the major pathogenetic differences that exist in 
terms of translocations and antigenic stimuli involved in the development of marginal zone 
lymphomas at different sites.42-44 When PCMZL is no longer distinguished from other 
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extranodal marginal zone lymphomas this may hamper elucidation of the pathogenesis of 
genuine PCMZL. 
The recognition of PCFCL and PCLBCL, LT as distinct disease entities in the 
WHO classification 2008 will definitely aid in the wider recognition of CBCL by 
hematopathologists and hematologists/oncologists worldwide. This will hopefully result in 
more uniform diagnosis and more appropriate management, leading to more homogeneous 
patient groups available for further studies. 
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Maligne lymfomen zijn kwaadaardige woekeringen van verschillende typen witte 
bloedcellen. Deze aandoeningen ontstaan meestal in lymfklieren, maar in ongeveer 40% 
van de patiënten presenteert het lymfoom zich in een zogenaamd extranodaal orgaan, zoals 
bijvoorbeeld de huid. De term primair cutaan lymfoom wordt gereserveerd voor lymfomen 
die zich primair in de huid manifesteren en waarbij op moment van diagnose geen 
lokalisaties buiten de huid (extracutaan) worden gevonden. Ongeveer 20-25% van alle 
primair cutane lymfomen bestaan uit proliferaties van maligne B-cellen, ook wel B-
lymfocyten genaamd. In de rest van de patiënten betreft dit vooral woekeringen van 
maligne T-lymfocyten. De studies beschreven in dit proefschrift hebben allen betrekking op 
cutane B-cel lymfomen.
In de sinds 2005 gebruikte WHO-EORTC classificatie voor primair cutane lymfomen 
worden 3 hoofdgroepen van primair cutane B-cel lymfomen (CBCL) onderscheiden: het 
primair cutaan marginale zone lymfoom (PCMZL), het primair cutaan follikel centrum 
lymfoom (PCFCL) en het primair cutaan difuus grootcellig B-cel lymfoom , been type 
(PCLBCL, LT). 
Het PCMZL wordt klinisch gekenmerkt door rode tot livide papels, plaques en nodi welke 
met name op de romp en de extremiteiten voorkomen. De prognose van deze lymfomen is 
gunstig met een 5-jaarsoverleving van bijna 100%. Histopathologisch bestaat deze entiteit 
uit een proliferatie van kleine B-lymfocyten , waaronder de marginale-zone B-cellen, 
lymfoplasmacytoïde cellen en plasmacellen.
Het PCFCL wordt klinisch gekenmerkt door solitaire of gegroepeerde plaques en tumoren, 
voornamelijk gelokaliseerd op het hoofd en de romp. Ook de prognose van deze groep is 
gunstig met een 5-jaarsoverleving van rond de 95%. Histopathologisch kan dit lymfoom 
een folliculaire, folliculair en diffuse of diffuse groeiwijze hebben en het infiltraat bestaat 
uit grote B-lymfocyten, welke een “gekliefd” aspect hebben (centrocyten en bijgemengde 
centroblasten). 
Het PCLBCL, LT tot slot, wordt gekenmerkt door nodi en tumoren welke zich vrijwel altijd 
op het been bevinden. In uitzonderlijke gevallen komen deze tumoren voor op andere delen 
van de huid. Histopathologisch wordt hierbij een diffuus infiltraat gezien bestaande uit 
grote, “ronde” B-lymfocyten, namelijk centroblasten en immunoblasten. 
Tot voor kort bestond veel discussie over de classificatie van primair cutane lymfomen. 
Verschillende classificatiesystemen werden naast elkaar gebruikt, zoals de EORTC 
classificatie voor primair cutane lymfomen uit 1997 en de WHO classificatie voor 
hematologische maligniteiten uit 2001. Met name de classificatie van primair cutane 
grootcellige B-cel lymfomen (PCFCL en PCLBCL, LT) was reden tot veel ophef. De 
discrepantie in het classificeren van deze lymfomen had belangrijke klinische en 
therapeutische consequenties. Met de publicatie  van de WHO-EORTC classificatie voor 
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cutane lymfomen in 2005 werd een consensus bereikt tussen aanhangers van de 
verschillende classificatiesystemen.
Er bleven echter enkele vragen onbeantwoord en deze hebben wij in dit proefschrift 
getracht te behandelen. Globaal kunnen drie aspecten onderscheiden worden: 1) Wat is de 
klinische toepasbaarheid van de nieuwe WHO-EORTC classificatie?, 2) Hoe valide zijn de 
prognostische parameters welke beschreven zijn in eerdere studies en welke geïdentificeerd 
werden in patiëntengroepen die gebaseerd waren op eerder gebruikte classificatiesystemen? 
en 3) Wat is het optimale management van de verschillende soorten CBCL zoals 
gedefinieerd in de WHO-EORTC classificatie?
In hoofdstuk 2 werden de klinische en histopathologische karakteristieken van 300 CBCL, 
welke opgenomen waren in de database van de Nederlandse Werkgroep Cutane Lymfomen 
en die geclassificeerd waren volgens de EORTC classificatie, gereviseerd en 
geherclassificeerd volgens zowel de WHO 2001 als de WHO-EORTC classificatie. 
Daarnaast werd met behulp van multivariabele analyse gezocht naar onafhankelijke 
prognostische factoren binnen de groepen primair cutane grootcellige B-cel lymfomen. Uit 
deze studie bleek dat de WHO-EORTC classificatie klinisch goed toepasbaar is en dat het 
relevante klinische en histopathologische parameters beschrijft voor de verschillende 
subgroepen. De nieuwe classificatie maakt een zinvol onderscheid in patiëntengroepen met 
een indolent en meer agressief klinisch beloop. Vergelijking met de eerder gebruikte 
classificaties toonde aan dat de consensus classificatie bijdraagt tot een adequatere indeling 
en dientengevolge meer uniforme behandeling van deze patiënten. Als belangrijkste 
prognostische factor binnen de groep van PCFCL werd gevonden dat tumoren gelokaliseerd 
op het been, in tegenstelling tot de tumoren elders op het lichaam, geassocieerd zijn met een 
significant slechtere prognose. 
Binnen de groep van PCLBCL, LT werden geen klinische of histopathologische parameters 
gevonden die onafhankelijk geassocieerd waren met prognose. Echter, in hoofdstuk 3 werd 
getracht eerdere veelbelovende resultaten te bevestigen, die beschreven dat verlies van een 
deel van chromosoom 9 geassocieerd is met een slechtere prognose in deze groep patiënten. 
In een Europese multi-centre studie werd met behulp van een nieuwe techniek, DNA van 
64 PCLBCL, LT patiënten geanalyseerd. Hierbij werd gevonden dat er inderdaad bij een 
groot deel van deze patiënten verlies is van een stukje van de korte arm van chromosoom 9. 
Dit stukje bevat het CDKN2A gen, dat codeert voor 2 eiwitten die dienen als tumor-
suppressor gen, namelijk p16 en p14/ARF. Patiënten met verlies van dit stukje DNA 
hadden een slechtere 5-jaarsoverleving dan patiënten zonder afwijkingen in dit gebied, 
namelijk 38% ten opzichte van 69% respectievelijk.
In hoofdstuk 4 werd gekeken naar de klinische toepasbaarheid en eventuele prognostische 
waarde van een nieuw beschreven classificatie systeem voor het rapporteren van ziekte-
uitgebreidheid in cutane lymfomen. Dit systeem werd gebaseerd op het Tumor, Node, 
Metastasis (TNM-) systeem, zoals dat ook gebruikt wordt bij verschillende solide tumoren 
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en melanomen. Wij pasten dit systeem toe op het geherclassificeerde cohort uit hoofdstuk 2 
en vonden dat het voorgestelde TNM-systeem goed toepasbaar is op de drie groepen CBCL 
en dat het de clinicus een handig instrument geeft voor het uniform registreren van 
uitgebreidheid van ziekte. Voor PCMZL en PCFCL heeft de T-score geen prognostische 
waarde. Voor patiënten met PCLBCL, LT is een oplopende T-score geassocieerd met een 
slechtere prognose.
In het laatste deel van het proefschrift werd gekeken naar twee aspecten van het 
management van verschillende groepen CBCL te weten, stagering en behandeling.
Met betrekking tot stagering werd in hoofdstuk 6 nagegaan of het zinvol is bij patiënten met 
in het huidbiopt de histologie van een indolent cutaan B-cel lymfoom (dus marginale zone 
lymfoom (MZL) of follikel centrum lymfoom (FCL)), in alle gevallen beenmergonderzoek 
te verrichten. Hiertoe werden de resultaten van beenmergonderzoek van 275 patiënten met 
in het huidbiopt kenmerken van een indolent B-cel lymfoom retrospectief geanalyseerd. 
Deze resultaten werden gecorreleerd met uitkomsten van overige stagringsonderzoeken 
(laboratorium- en beeldvormend onderzoek) en overlevingsdata. In de groep van 82 MZL 
hadden twee patiënten een positief beenmergbiopt bij diagnose, waarbij bij één patiënt dit 
de enige aanwijzing was voor extracutane ziekte. Deze patiënt had net als de patiënten 
zonder aanwijzingen voor extracutane ziekte een 5-jaarsoverleving van 100%. Echter, in de 
groep van 193 FCL patiënten, hadden 22 patiënten een positief beenmerg en bij negen van 
hen was dit de enige extracutane lokalisatie. Deze negen patiënten hadden echter wel een 
significant slechtere 5-jaarsoverleving in vergelijking met de patiënten zonder extracutane 
ziekte (respectievelijk 63% versus 95%). Uit deze resultaten werd geconcludeerd dat 
beenmergonderzoek een essentieel onderdeel is van het stageringsonderzoek bij patiënten 
met een FCL in de huid en dat voor patiënten met een MZL in de huid, een beenmergbiopt 
alleen overwogen zou hoeven te worden wanneer andere onderzoeken aanwijzingen geven 
voor aanwezigheid van extracutane ziekte.
Tot slot werd onderzoek gedaan naar de optimale behandeling van de drie CBCL entiteiten. 
Aangezien radiotherapie (RT) al sinds de eerste beschrijvingen van lymfomen in de huid, 
gebruikt wordt voor de behandeling van deze ziekte, werden in het onderzoek beschreven 
in hoofdstuk 6, de resultaten van dit type behandeling geanalyseerd op de nieuw 
gedefinieerde entiteiten. Uit dit retrospectieve onderzoek bleek dat alle drie de subgroepen 
een goede initiële reactie vertonen op bestraling, met een complete remissie in bijna 100% 
van de gevallen. Echter, een aanzienlijk deel van de mensen met een PCLBCL, LT vertoont 
extracutane progressie na RT behandeling en uiteindelijk overlijdt 41% aan de gevolgen 
van het lymfoom. In de groep van PCFCL moet een onderscheid gemaakt worden tussen 
patiënten met huidafwijkingen op het been en elders op het lichaam. Patiënten met 
afwijkingen op het been hebben namelijk een significant hoger recidiefpercentage, vaker 
extracutane disseminatie en een veel lagere 5-jaars ziekte-specifieke overleving.  
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Concluderend kan gezegd worden dat radiotherapie een veilige en effectieve behandeling is 
bij PCMZL en PCFCL, maar dat het geen eerste keus behandeling is voor mensen met 
PCLBCL, LT en mensen met PCFCL gelokaliseerd op het been.
In hoofdstuk 7 werden de resultaten van de studies beschreven in hoofdstukken 4, 5 en 6 
geïntegreerd en aangevuld met de resultaten van een uitgebreide literatuur studie en 
discussies binnen een multidisciplinair panel van experts op het gebied van cutane 
lymfomen. Op deze manier was het mogelijk consensus richtlijnen op te stellen voor de 
behandeling van de drie CBCL entiteiten. Deze richtlijnen staan beschreven in Tabel 4 van 
hoofdstuk 7.
Samenvattend tonen de studies beschreven in dit proefschrift dat de WHO-EORTC 
classificatie een vooruitgang heeft betekend in de classificatie van patiënten met een CBCL 
en dat het bijdraagt tot adequate en meer uniforme behandeling van deze zeldzame groep 
patiënten. De definities van PCFCL en PCLBCL, LT zijn dan ook ongewijzigd 
overgenomen in de recent gepubliceerde nieuwe versie van de WHO classificatie voor 
hematologische tumoren. Het PCMZL wordt helaas onderdeel van de bredere groep van 
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